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CHAPTER I 
 
INTRODUCTION 
 
General Introduction to p120 and its cellular functions 
 p120 was originally described as a Src substrate and subsequently designated a 
catenin, a protein that interacts with and modulates function of cadherins (Reynolds et al.,  
1989, Reynolds et al., 1994, Daniel and Reynolds, 1995, Shibamoto et al., 1995).  
Cadherins are a critical family of proteins involved in tissue homeostasis, morphogenesis, 
and cancer that mediate cell-cell adhesion by forming homodimers between adjacent cells 
(reviewed in Takeichi, 1995, in Yap, 1998, in Gumbiner, 2005).  p120 is the prototypical 
member of a family of armadillo-repeat proteins that includes δ-catenin (δ-ctn), ARVCF, 
p0071, and plakophilins (Anastasiadis and Reynolds, 2000).  p120 lacks enzymatic 
activity and primarily acts as a scaffolding protein by bringing together and modulating 
dynamic protein complexes (Figure 1).  p120 binds and stabilizes cadherins at the plasma 
membrane, while α catenin and β catenin (β-ctn) physically and/or functionally link 
cadherins to the actin cytoskeleton (Rimm et al., 1995, Yamada et al, 2005).  p120 is also 
known to modulate actin cytoskeleton dynamics by regulating the activity of 
RhoGTPases and may mediate transcriptional response through interactions with Kaiso 
and Wnt signaling (reviewed in van Roy and McCrea, 2005, in Anastasiadis 2007, in 
Daniel, 2007). 
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Cadherin stabilizing function of p120 
 p120 functionally interacts with the entire cadherin complex by physically 
binding to and stabilizing classical cadherins.  p120 binds to the juxtamembrane domain 
(JMD) of classical cadherins (e.g. E-, N-, and VE-cadherin) (Thoreson et al., 2000).  
Indeed, a triple-alanine mutation in the JMD leads to uncoupling of this interaction.  
Conversely, cadherins interact with armadillo repeats 1-5 of p120 (Ireton et al., 2002).  
Experiments with p120-deficient SW48 cells demonstrate that expression of mutant p120 
lacking any one of these arm domains results in destabilized cadherins and reduced cell-
cell adhesion.  E-cadherin protein half-life is doubled when p120 is re-expressed, without 
changes to mRNA levels, indicating the mechanism of p120 control of cadherin involves 
protein stabilization (Ireton et al., 2002).  Direct evidence for the cadherin stabilizing 
function comes from work utilizing shRNA depletion of p120 (Davis et al, 2003).  
Resident cadherin (e.g. E-cadherin in epithelial cells, VE-cadherin in endothelial cells) 
depletion is the direct result of p120 depletion, thus p120 acts as a rheostat of cadherin 
levels.  This concept is strongly supported in vivo as most tissues in which p120 is 
experimentally ablated demonstrate significant reduction of junctional cadherins (Elia et 
al., 2006, Davis et al., 2006, Perez-Moreno et al., 2006, Bartlett et al., 2010, Oas et al., 
2010, Smalley-Freed et al., 2010, Smalley-Freed et al., 2011, Marciano et al., 2011, Stairs 
et al., 2011, Chacon-Heszele et al., 2012).  The mechanism likely involves inhibition of 
endocytosis, as p120 binding specifically prevents clathrin-dependent endocytosis of 
cadherins (Xiao et al., 2005) and masks a dileucine motif in E-cadherin that is necessary 
for this process (Miyashita and Ozawa, 2007).  Recently, the crystal structure of p120 
binding to the JMD of E-cadherin was resolved (Ishiyama et al., 2010), revealing the 
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molecular basis for uncoupling by the triple alanine mutations in E-cadherin (above) as 
well as individual amino acids in p120 that disrupt interaction with cadherins when 
mutated  (i.e. K401, K444, N478).        
  
Activity modulation of Rho family GTPases by p120 
 Rho family small GTPases function as binary switches that control important 
cellular processes, such as adhesion and motility.  They are active or inactive when bound 
to GTP or GDP, respectively (reviewed in Jaffe and Hall, 2005).  p120 modulates the 
activity of one such GTPase, RhoA, by a variety of non-mutually exclusive mechanisms. 
In NIH-3T3 fibroblasts, Rho inhibition leads to a striking branching phenotype that is 
phenocopied by overexpression of wildtype p120, but not by a 622-628 amino acid 
deletion mutant (Anastasiadis et al., 2000).  p120 is proposed to bind directly to RhoA 
through p120 tyrosine 112 and/or amino acids 622-628 (Castano et al., 2007, Yanagisawa 
et al., 2008).  These data suggest a model wherein p120 binds RhoA and keeps it in an 
inactive GDP-bound state (i.e. a guanosine dissociation inhibitor role).  Alternatively, 
p120 binds p190 Rho GTPase activating protein (GAP), an inactivator of RhoA, thereby 
recruiting it to the cadherin complex to mediate local Rho inhibition (Wildenberg et al., 
2006).  While multiple mechanisms have been identified, p120 clearly inhibits RhoA in 
vitro and in vivo (Perez-Moreno et al., 2006).  Interestingly, p120 may also promote local 
RhoA activity by its physical interaction with ROCK, a downstream effector of Rho 
(Smith et al., 2011, 2012).  In turn, ROCK directly phosphorylates p120 on serine 268 
(Smith et al., 2012- dissertation).  While the significance of this observation remains 
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unclear, it indicates that this signaling is bidirectional and suggests a possible feedback 
loop. 
 p120 also modulates the activity of another Rho family member, Rac1, typically 
leading to its activation (Noren et al., 2000, Goodwin et al., 2003, Yanagisawa and 
Anastasiadis, 2006, Soto et al., 2008, Johnson et al., 2010).  In MBA-MD-231 and Neu-
transformed MCF10A cells, p120 activates Rac1 to promote cell growth and invasion 
(Soto et al., 2008, Johnston et al., 2010).  However, in another transformed breast cell 
line, MCF7, p120 suppresses Rac1 activation (Soto et al., 2008).  The authors propose 
that the difference in signaling between 231 and MCF7 cells is the cadherin present in the 
cell (i.e. cadherin-11 in 231 cells and E-cadherin in MCF7 cells) but other possibilities 
were not ruled out. 
 p120 is important for not only the control of Rac and Rho individually, but likely 
plays a critical role in the crosstalk between the two GTPases.  Rac inhibits Rho through 
a well-characterized signaling pathway, known as the Bar-Sagi pathway (Nimnual et al., 
2003).  We have shown that this pathway is also dependent on p120 and p190RhoGAP 
(Wildenberg et al., 2006), and the interaction between p120 and p190RhoGAP requires 
Rac activation (Birukova et al., 2010).  Based on these data, it has been suggested that 
p120 functions as a nexus for Rac1 and RhoA signaling.   
 
p120 binding partner Kaiso and its connections to Wnt signaling 
 The p120 binding partner, Kaiso, is a member of the BTB/POZ-ZF (broad-
complex, tramtrack, bric-a-brac/poxvirus and zinc finger) subfamily of transcription 
factors (Daniel and Reynolds, 1999).  The interaction occurs via p120 ARM repeats 1-5 
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and the ZF domain of Kaiso (Daniel and Reynolds, 1999), but its significance is unclear.  
p120 has been proposed to sequester Kaiso in the cytoplasm, thus preventing its 
transcriptional action in the nucleus (reviewed in Daniel, 2007) and several variations on 
this theme have been suggested (Kim et al., 2004, Spring et al., 2005, Park et al., 2006, 
Del Valle-Perez et al., 2011).  Kaiso-mediated repression of transcription is proposed to 
occur through bimodal DNA binding: either through a Kaiso consensus sequence or CpG 
methylation sites (Prokhortchouk et al., 2001, Daniel et al., 2002, Yoon et al., 2003).  
Moreover, Kaiso physically interacts with a number of proteins via its N-terminal POZ 
domain, including those involved with mediating transcription (Yoon et al., 2003, 
Defossez et al., 2005). For example, Kaiso directly binds nuclear receptor co-repressor as 
part of its mechanism of interacting with CpG islands (Yoon et al., 2003).  Together, 
these data show that Kaiso generally functions in transcriptional repression.  
 Fellow adherens junction member, β-catenin, is a key player in Wnt signaling, 
and recent work suggests a role for p120 in this pathway as well.  Wnt ligand activation 
of receptor complexes (e.g. Frizzled/LRP) leads to β-catenin stabilization, translocation 
into the nucleus, and interaction with transcription factors (e.g. TCFs) that activate β-
catenin target genes (e.g. c-Myc)(reviewed in Gordon and Nusse, 2006).  This pathway is 
essential for development and is often misregulated in cancer (reviewed in Nusse, 2005 
and in Logan and Nusse, 2004).   
 p120 is suggested to modulate Wnt signaling via its binding partner Kaiso, which 
is reported in a Xenopus laevis model to directly repress both canonical and non-
canonical Wnt signaling (Kim et al., 2004, Park et al., 2005, 2006).  Kaiso is a repressor 
of non-canonical Wnt-11 and overexpression of p120 relieves this repression (Kim et al., 
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2004).    Similarly, Kaiso represses canonical Wnt target genes (e.g. siamois, cyclin-D1, 
and c-Myc) by binding to and sequestering TCF (Park et al., 2005).  In a mechanism 
involving Frodo and Dishevelled, two Wnt signaling proteins, p120 prevents Kaiso from 
entering the nucleus and acting to suppress Wnt target genes (Park et al., 2006).  
However, the mechanism of Kaiso control of Wnt signaling, and Kaiso function during 
Xenopus gastrulation in general, has been called into question (Ruzov et al., 2009a, 
2009b).  Recent evidence suggests that rather than directly interacting with Wnt target 
gene promoters, Kaiso binds and sequesters TCF3 away from its promoter targets (Ruzov 
et al., 2009a, 2009b).  In human cell lines, a similar model of mutual exclusion has been 
proposed wherein TCF4 or β-ctn binds to Kaiso to sequester them away from their 
respective promoter binding sites (Del Valle-Perez et al., 2011).  Therefore, the exact 
mechanism of Kaiso-p120 interaction in Wnt signaling remains to be fully understood. 
p120 is also proposed to participate in Wnt signaling by Kaiso-independent 
mechanisms.  In sw480 colon carcinoma cells upon Wnt activation, p120 binds to and is 
phosphorylated by casein-kinase 1ε at serines 268/269.  Disruption of this interaction by 
p120 depletion prevents numerous downstream aspects of Wnt signaling suggesting that 
p120 is required for Wnt signaling (Casagolda et al., 2010).  While preliminary, these 
findings suggest a role for p120 in the initial steps of Wnt pathway activation.  
 
p120 versus its family members 
 p120 family members are proposed to execute functions redundant to p120.   For 
example, all four core family members, p120, ARVCF, p0071 and δ-ctn, bind and 
stabilize cadherins in vitro (Thoreson et al., 2000, Ireton et al., 2002, Davis et al., 2003, 
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Hatzfeld et al., 2003, Calkins et al., 2003, Setzer et al., 2004).  If p120 is depleted in 
A431 cells using shRNA, expression of either ARVCF or δ-ctn can rescue cadherin 
stability (Davis et al., 2003).  However, the scenario in vivo may be more complicated.   
While redundancy has  been proposed in some organ systems to compensate for p120 
loss (Perez-Moreno et al., 2006), the issue of redundancy has been complicated by a lack 
of good antibodies.  High quality antibodies that are compatible with IHC have been 
recently developed and are beginning to clarify the specific expression patterns and 
contribution of each family member in vivo  (Walter et al., 2008, 2009, 2010). 
 Evidence is mounting that p120 and its core family members perform non-
redundant functions.  The global p120 null mouse is embryonic lethal suggesting that 
p120 is essential for mammalian life, and family members do not overcome its loss  
(Davis et al., 2006).  On the flip side, ARVCF, p0071, and δ-ctn perform functions and 
are involved in disease states in ways not attributed to p120 (Hatzfeld and Nachtsheim 
1996, Sirotkin et al., 1997, Medina et al., 2000, Izawa et al., 2002, Jaulin-Bastard et al., 
2002, Laura et al., 2002, Martinez et al., 2003, Kausalyn et al., 2004, Wolf et al., 2006).  
Most notably, the PDZ domain in the C-terminus of these family members confers 
physical and functional interaction with other PDZ domain containing proteins.  ARVCF 
binds to tight junction protein ZO-1 (Kausalyn et al., 2004) and p0071, δ-ctn, and 
ARVCF bind erbin, a polarity protein (Izawa et al., 2002, Jaulin-Bastard et al., 2002, 
Laura et al., 2002).  Thus, the presence of their PDZ domain links them to polarity 
complexes and tight junctions.  This difference in p120, is hypothesized to allow p120 to 
have evolved unique and specified functions (reviewed in McCrea and Park, 2006, 
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Carnahan et al., 2010).  However, the significance of this difference, as well as others 
(e.g. splicing in only p120 and ARVCF), has yet to be elucidated.    
 
p120 Ablation in Model Organisms 
Ablation studies in model organisms provide important perspective into the roles 
of p120 in different species and organ systems.  In vitro, p120 depletion causes cell-cell 
adhesion defects and alterations to key signaling nodes (e.g. Rho family GTPases).  
Similar effects are observed in vivo, but the physiological effects are more complex 
(Table 1).  
Surprisingly, the effects of p120 ablation in invertebrates are relatively mild, 
despite the presence of only one p120 family member (Table 1).  For example, loss of 
Jac-1, the closest homologues of p120 in Caenorhabditis elegans, does not affect 
viability or generate a discernable phenotype.  Likewise, the only p120 homologue 
present in Drosophila is not essential for life (Myster et al., 2003, Magie et al., 2002).  
However, ablation of these homologues exacerbates phenotypes driven by mutations in 
other adherens junction proteins suggesting that, despite its overall non-essential 
function, it serves a function in invertebrates (e.g. positive regulation of adhesion) (Pettitt 
et al., 2003, Myster et al., 2003).    Evolutionary analysis of p120 and its family members 
suggests that the invertebrate p120 genes are functionally analogous to δ-catenin, rather 
than the gene duplication product that is vertebrate p120 (Carnahan et al., 2010).  
Therefore, while the minor consequences of invertebrate p120 loss seem unexpected, 
these data likely reflect specific evolution-driven divergence of p120 structure and 
function only acquired by vertebrates. 
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In contrast to invertebrates, global loss of p120 in mice is embryonic lethal, and 
phenotypes associated with tissue-specific ablation are quite severe (Table 1).  In fact, 
tissue-specific knockout of p120 in vasculature, salivary gland, or the GI tract leads to 
death (Oas et al., 2010, Davis et al., 2006, Smalley-freed et al., 2010).  Mice die in utero 
due to p120-ablation in the vasculature and subsequent hemorrhaging (Oas et al., 2010).  
Tissue-specific ablation of p120 in the salivary gland prevents acini development and 
ultimately leads to perinatal death (Davis et al., 2006).  In the GI tract, p120 loss induces 
severe deterioration of the gut epithelium and terminal bleeding (Smalley-Freed et al., 
2010).  While ablation of p120 in the teeth and skin does not induce death, these mice 
exhibit considerable wasting, tooth erosion, and epidermal hyperplasia (Bartlett et al., 
2010, Perez-Moreno et al., 2006).  A notable exception to the severity of p120 ablation is 
in the adult prostate gland, which does not demonstrate a phenotype, despite induction of 
extensive p120 ablation (ABR unpublished results).  In general, the absence of p120 
leads to cell-cell adhesion defects and disruption of tissue homeostasis, however tissue-
specific differences exist.   
Numerous factors contribute to the tissue-specific phenotypes caused by p120 
ablation.  For example, tissue structure plays a role in the outcome of p120 loss.  Simple 
and bilayered epithelia exhibit significant adhesion defects in the absence of p120, 
whereas stratified epithelia without p120 are protected from cell sloughing.  Even within 
a given tissue, different structural constraints influence the outcome of p120 ablation.  In 
the mammary gland, ducts without p120 are partially malformed but exhibit some degree 
of cell-cell adhesion.  In contrast, p120 null cells localized to the terminal end buds are 
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wholly dissociated from the functional unit likely stemming from an inability of the null 
cells to participate in the dynamic rearrangements of this structure (Chapter 3).  In the GI 
tract, cell sloughing is more extensive once p120 null cells reach the tips of the villi 
where sheer stress is more prominent, further reflecting the role of tissue structure on the 
fate of cells lacking p120 (Smalley-Freed et al., 2010).  The degree of environmental 
exposure is also likely to mediate tissue specific effects. In the GI tract, destruction 
induced by p120 ablation coincides with the transition from a relatively sterile 
environment to colonization by the gut flora.  Prior to this transition, the epithelium 
remains relatively intact suggesting that exposure to external factors like the bacteria 
ridden GI lumen contribute to the consequence of p120 loss.  Finally, the timing and 
context of the knockout may explain tissue specific differences.  p120 ablation is 
catastrophic to the developing salivary and mammary glands, whereas loss in the adult 
prostate does not generate a detectable phenotype (Davis et al., 2006, chapter 3). These 
findings suggest that p120 loss during key morphogenetic processes is highly detrimental 
while loss in a more stable adult tissue is better tolerated. 
p120 stabilizes endogenous classical cadherins in all cell and tissue types 
examined to date, however the subsequent effects on cell-cell adhesion are variable.  The 
effect of p120 ablation is specific to classical cadherins and the adherens junction, as 
other junctions (e.g. desmosomes and tight junctions) are not significantly affected by 
p120 depletion (Smalley-freed et al., 2020, Davis et al., 2006). Ablation of p120 in the 
epidermis, GI tract, or salivary gland reduces cadherin levels by approximately 50%, 
whereas in the prostate and mammary glands, cadherins are near absent  (Smalley-freed 
et al., 2006, Perez-Moreno et al., 2006, Davis et al., 2006, Chapter 3).  Despite similar 
 13 
reduction in cadherins, the p120-ablated gut suffers from adhesion and barrier defects, 
whereas the skin maintains barrier function.  Furthermore, near complete downregulation 
of cadherins in the absence of p120 appears to be responsible for major adhesion defects 
in the mammary gland but has no effect on cell-cell attachment in the prostate.  Thus, the 
degree of cadherin destabilization in the absence of p120 in vivo and its consequences are 
variable. 
The contributions of cadherin-dependent and -independent functions of p120 in 
vivo are beginning to be elucidated.  In many organ systems, such as the mammary gland 
and the vasculature, the loss of cadherin appears to be the dominant driver of p120 
ablation-induced phenotypes (Davis et al., 2006, Oas et al., 2010, Bartlett et al., 2010, 
Chapter 3). However, cadherin-independent functions also contribute to p120 ablation-
induced phenotypes.  For example, loss of p120 in the epidermis relieves inhibition of 
Rho, consistent with in vitro data, and causes NFkB activation and inflammation (Perez-
Moreno et al., 2006).  Activation of Rho is also attributed to phenotypes in other p120 
knockout tissues  (Stairs et al., 2011, Elia et al., 2006).  As more sophisticated methods 
are employed to study p120 in vivo, the role of cadherin-independent functions of p120 
(e.g. modulation of binding partners) will be addressed. 
Despite extensive pathology literature demonstrating a correlation between p120 
loss and tumor progression (reviewed in Thoreson and Reynolds, 2002), only recent 
studies in mice have provided definitive evidence for p120 as a bona fide tumor 
suppressor.  In the GI tract and esophagus, p120 knockout induces the formation of 
adenomas and invasive cancer, respectively (Smalley-freed et al. 2011, Stairs et al. 2011). 
Ablation of p120 also induces precancerous intraepithelial neoplasia and hyperplasia in 
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the salivary gland and skin, respectively (Davis et al., 2006, Perez-Moreno et al., 2006).  
In vitro studies using a tumorigenesis assay, anchorage-independent growth in soft agar, 
demonstrate that p120 is required for tumor formation driven by oncogenic Src or Rac1 
(Dohn et al., 2009). These findings may be relevant to some in vivo systems since 
adenomas formed in p120-ablated GI tracts retain p120 (Smalley-Freed et al., 2011).  On 
the other hand, tumors lacking p120 form in the esophagus, oral cavity, and squamous 
forestomach suggesting that there are organ specific requirements for p120 during tumor 
initiation (Stairs et al., 2011). 
Inflammation, albeit derived by different mechanisms, is common to all these 
tumor models (Perez-Moreno et al., 2006, Smalley-Freed et al., 2010, Stairs et al., 2011).  
Cell autonomous activation  of NFkB induces infiltration of immune cells in the skin and 
esophagus, whereas this inflammatory response may be the secondary effect of a barrier 
defect in the GI tract.  Interestingly, knockout epithelia (e.g. kidney and mammary) that 
do not exhibit an immune cell infiltration, also not do not develop tumors (Marcinao et 
al., 2011, chapter 3). Furthermore, the common feature of tumor formation in p120-
depleted mice is an inflammatory response suggesting that stromal events may contribute 
to tumor initiation or progression.  Indeed, a causative role for this immune cell response 
was demonstrated with p120 ablation in the epidermis and esophagus (Perez-Moreno et 
al., 2006, 2008, Stairs et al., 2011).  Knockout mice treated with dexamethasone, an 
immune suppressant, exhibit blockade of neoplasia formation or progression to invasion 
in the epidermis and esophagus, respectively.  Thus, p120 loss may induce tumor 
formation by regulating the microenvironment, specifically the immune system. 
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 Collectively, these data highlight the importance of p120 in maintaining tissue 
homeostasis and in developmental processes.  However, dynamic regulation of p120, not 
simply its presence, is likely necessary to adapt to a wide variety of tissue-specific 
scenarios.  The precise role of p120 levels in the context of mouse models of diseases, 
such as cancer, remains to be addressed. 
 
Importance and regulation of p120 levels 
 A wealth of recent evidence indicates that p120 levels are critical for proper tissue 
development and homeostasis (Figure 2).  It is increasingly clear that precise control of 
p120 levels is multifaceted with regulation occurring at many stages of p120 production 
(Figure 3).  Furthermore, disease states, such as cancer, manipulate p120 status during 
their initiation, maintenance, and progression.   
In vitro, altered p120 expression disrupts normal cellular function (Figure 2).  For 
example, over-expression of p120 in NIH-3T3 cells induces a striking branching 
phenotype, while p120 depletion induces extensive actin stress fiber formation 
(Anastasiadis et al., 2000, Wildenberg et al., 2006). Similarly in epithelial cells, over-
expression or knockdown of p120 has dramatic effects on morphology and actin 
distribution (Aho et al. 2002, Boguslavsky et al. 2007).  Clearly, proper p120 levels, 
while context dependent, are directly responsible for maintenance of the normal cellular 
state. 
Dysregulation of p120 expression in a variety of cancer types is well documented 
(reviewed in Thoreson and Reynolds, 2002, van Hengel and van Roy, 2007).  For 
example, modulation of p120 levels in often associated with transition to or progression 
2D
3D
High/
Overexpressed
p120 levels
Normal Low/
Knockout
Figure 2. The importance of p120 levels
A schematic of the consequences of p120 expression levels in 2-D 
and 3-D. Normal p120 levels support cell-cell adhesion and tissue 
architecture (middle), over-expression leads to cell arborization on 
plastic and emboli formation in some cases (left), low p120 levels 
lead to a loss of cell-cell adhesion and a breakdown of tissue archi-
tecture (right). 
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Figure 3. The life cycle of p120
A schematic of the life-cycle of p120. One the genomic level, p120 expression 
is controlled by monoallelic inactivation (1).  p120 transcription is mediated by 
FoxC2 and possibly other transcription factors (2). Multiple alternative start 
sites regulate the isoform of p120 to be expressed.  Translation of p120 
mRNA occurs via cap-dependent translation under normal conditions, or by 
IRES-dependent mechanisms under stress conditions (3). At the post-
translational stage, p120 is extensively modified by a number of kinases and 
phosphatases (4), while protein stability is regulated by degradation
mechanisms (5).
17
 18 
 of breast cancer.  10% of ductal breast cancers exhibit regions of complete loss, whereas 
p120 is relegated to the cytoplasm in most lobular breast cancers due to E-cadherin loss 
(Dillon et al., 1998, Nakopoulou et al., 2002, Sarrio et al., 2004).  On the other hand, 
upregulated p120 is required for inflammatory breast cancer emboli formation suggesting 
that tumors differently alter p120 status to accommodate unique environmental 
requirements (Silvera et al., 2009).  Interestingly, p120 is hijacked by N. meningitidis to 
form ectopic early junction-like domains with the endothelial cells, allowing the 
bacterium to cross the blood brain barrier (Coureuli et al. 2009).  Given the importance of 
cellular amounts of p120, regulation of p120 at a variety of stages is likely to be 
advantageous.  
 
Monoallelic inactivation 
 The p120 gene is located on human chromosome 11q11 (CTNND1) and mouse 
chromosome 2 (ctnnd1) (Reynolds et al., 1996, Mo and Reynolds, 1996, and Keirsebilck 
et al., 1998).  Interestingly, a recent study using asynchronous DNA replication identified 
p120 as subject to random monoallelic inactivation, a process whereby a single allele of a 
gene is silenced by epigenetic means (Gimelbrant et al., 2005).  This effect on p120 
appears to be widespread as fibroblasts, B-cells, and embryonic stem cells all exhibit 
inactivation events (Gimelbrant et al., 2005, Dutta et al., 2009). Monoallelic inactivation 
of p120 leads to decreased protein levels suggesting that the active allele does not 
compensate for inactivation of the other.  However, this does not rule out the possibility 
that alterations to post transcriptional processes can compensate for total protein levels.  
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This finding not only adds to the understanding of p120 level regulation but also presents 
a potentially useful model for studying drivers and modifiers of monoallelic inactivation.  
  
Transcription, splicing, and translation 
 There is a high degree of complexity to p120 at the mRNA transcript level (Figure 
4). In mammals, four alternative translational start sites as well as three alternatively 
spliced exons (i.e. A, B, and C) in the 3’ region suggest a potential 32 different isoforms 
(Mo and Reynolds et al. 1996, Keirseblick et al. 1998). Isoform 1 is the predominant 
p120 isoform in mesenchymal cells (e.g. fibroblasts) while epithelial cells predominantly 
express isoform 3 (Mo and Reynolds, 1996).  However, this is likely an 
oversimplification as multiple isoforms of p120 are expressed in cancer cell lines and 
tumor samples (Sarrio et al., 2004). 
  Evidence for distinct roles of p120 isoforms is emerging. Interestingly, a switch 
from p120 isoform 3 to isoform 1 is observed concomitant with cadherin switching 
and/or loss during epithelial-to-mesenchymal transition (EMT) (Sarrio et al., 2004, 
Slorach et al., 2011). This finding likely relates to invasive potential as isoform 3A 
blocks where as 1A facilitates invasion in 3D cultures (Slorach et al., 2011).  This is 
echoed in NIH-3T3 and MDA-MB-231 cells where expression of isoform 1A, but not 
4A, inhibits RhoA and ultimately promotes invasion (Yanagisawa et al., 2008).  In 
contrast, in lung cancer cells, isoform 1A inhibits invasion and 3A does not alter invasion 
but rather inhibits cell-cycle progression (Liu et al., 2009).  While there are notably cell 
specific differences, it is clear that p120 isoforms are not equivalent in their intracellular 
functions. 
Y96, Y112, Y217, Y228, Y257,
Y280, Y291, Y296, Y302, Y904
S122, S252, S268, S269, S288, 
T310, S312, S879, T916
Tyrosine Phosphorylation Serine/Threonine Phosphorylation
p120 1ABC
Alternative
ATG Start Sites
CC Regulatory
Armadillo Repeat Domain
Figure 4. p120 isoforms and phosphorylation
The schematic of full length p120 isoform 1ABC and shorter isoform 3ABC 
are shown.  The structural elements are as follows: coiled-coiled domain 
(pink), regulatory domain (green), armadillo repeats (yellow), exons (blue).  
Note the 4 isoforms formed by alternative ATG start sites.  Tyrosine and 
serine/threonine sites are depicted as red and black circles, respectively. 
Cells undergoing EMT switch from isoform 3 to 1 and those undergoing 
MET from 1 to 3.
p120 3ABC
EMTMET
Sessile Cells
(Epithelial)
Motile Cells
(Fibroblasts)
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 The presence of C-terminal alternatively spliced exons in p120 adds to transcript 
complexity but the advantage and/or function of these events is largely unknown.  Most  
ectopic expression studies have used p120 cDNAs containing only exon A.  While this is 
the most common exon found in transcripts (Keirseblick et al., 1998), such experimental 
designs necessarily prevent the understanding of other exons.  Exon B contains a 
functional nuclear export signal and p120 phosphorylation at S879 occurs only in the 
presence of exon A (van Hengel et al., 1999, Vaughan et al., 2007).   
 Novel mechanisms of p120 transcription, splicing, and translation are beginning 
to be identified.  The first, and currently only, published study of the p120 promoter  
identified putative cis-acting transcriptional elements, including FOXC2, by in silico 
analysis (Mortazavi et al., 2010).  RNAi-mediated depletion of FOXC2 increases p120 
mRNA transcripts and protein levels, and ChIP analysis indicates direct binding of 
FOXC2 to the endogenous p120 promoter, thus confirming its role as a transcriptional 
repressor of p120.  Interestingly, FOXC2 also promotes EMT, which, as noted above, is 
associated with p120 isoform 1 to 3 switch (Mani et al., 2007, Slorach et al., 2011).  
Conversely, recent studies identify splicing factors, ESRP1 and ESPR2, as keepers of the 
epithelial phenotype.  When present, these factors promote splicing of a group of 
transcripts, including p120, to generate the epithelial form of that protein (e.g. p120 
isoform 3) (Warzecha et al. 2009, 2010). 
 Adding to the complexity, p120 transcripts contain internal ribosomal entry sites 
(IRES) in their 5’ UTRs that are utilized for translation during cellular stress, nutrient 
deprivation, or hypoxia (reviewed in Silvera et al., 2010).  Using a model of 
inflammatory breast cancer (IBC), Silvera and colleagues demonstrate that up-regulation 
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of p120 in emboli is necessary for increased E-cadherin stability, which provides a 
survival signal crucial for the etiology of IBC (Silvera et al., 2010).  p120 is up-regulated 
by increased expression of the translation initiation factor eIF4G, which drives a switch 
from cap-dependent to IRES-mediated, cap-independent translation of p120 mRNA 
(Silvera et al., 2009). p120 over-expression is necessary for the development of IBC 
emboli suggesting that p120 does not act as a classical tumor suppressor in all contexts.  
Collectively, this work provides the first insights into control of p120 at the levels of 
transcription, splicing, and translation while demonstrating the intricacy of p120 
regulation that continues to emerge.  
 
Post-translational modifications and protein stability 
 p120 is extensively phosphorlyated but the role of this modification is not well 
understood (reviewed in Reynolds and Rocniak-Ferguson, 2004).  Phosphorylation 
events on a multitude of tyrosine, serine, and threonine residues of p120 have been 
mapped and are shown in figure 4 (Mariner et al., Xia et al., Luo et al., 2008, Casagolda 
et al., 2010).  p120 is known to directly bind a number of kinases and phosphatases 
(Keilhack et al., 2000, Holsinger et al., 2002, Piedra et al., 2003, Castano et al., 2007, 
Casagolda et al., 2010, Wong et al., 2010, Smith et al., 2012).  Most of the 
phosphorylation sites of p120 are housed in the N-terminal regulatory domain.  This 
domain is known to coordinate receptor tyrosine kinase signaling regulation of motility, 
thus intimating a role for phosphorylation (Cozzolino et al., 2003).  Furthermore, specific 
phosphorylation events in this domain have been shown to affect cell-cell adhesion, 
although these findings are context and cell line specific (Kim and Wong, 1995, Piedra et 
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al., 2003, Xu et al., 2004, Calautti et al., 1998, 2002).  Interestingly, no defects in cell-cell 
adhesion or alteration to the actin cytoskeleton are present when either all the 
serine/threonine or tyrosine sites are mutated to be phosphorylation-deficient (Xia et al., 
2006, Mariner et al., 2001). 
 The degradation pathways that modulate p120 levels are beginning to be 
identified.  As with β-ctn, p120 levels may be modulated by Wnt signaling and the 
proteasome (Hong et al., 2010).  Work in Xenopus laevis suggest GSK3β and Axin 
facilitate a cascade of events, including phosphorylation and ubiquitylation of p120, 
which ultimately lead to proteasome-mediated degradation of p120 (Hong et al., 2010).  
Furthermore, Frodo, part of the Wnt pathway, binds p120, resulting in its stabilization 
(Park et al., 2006).  Overall, Wnt signaling may control the levels of more than just β-
catenin (Park et al., 2006, Oh et al., 2009, Hong et al., 2010). 
 The protease calpain is emerging as a key player in p120 degradation. Culture of 
neuroblastoma cells under hypoxic and hypoglycemic conditions rapidly induces 
activation of calpain and reduction of p120 protein (Ohno et al., 2007).  In human 
bronchial cells and mouse lungs, induction of inflammation by lipopolysaccharide (LPS) 
treatment results in rapid loss of p120 protein without changes to p120 mRNA, 
suggesting that LPS induces degradation of p120 (Wang et al., 2010, Wang et al., 2011).  
Interestingly, tyrosine phosphorylation may play a role in LPS-induced degradation 
(Gong et al., 2008).  Since LPS is known to induce calpain activity, it is possible that 
calpain mediates the effect on p120 (Li…Peng et al., 2009).  In another scenario, 
exogenous expression of δ-catenin induces redistribution of p120 to the cytoplasm where 
it may be degraded (Yang et al., 2010).  This effect can be subtly reduced by a calpain 
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inhibitor, which also blocks the proteasome at these amounts, suggesting that either factor 
may be contributing. Whether these effects are mediated by direct interaction with and 
cleavage by calpain, as well as the role the proteasome in this process, has yet to be fully 
addressed. 
 
p120 effectors in mammary development 
General mammary development 
 The life cycle of the mouse mammary gland involves a complex orchestration of 
events and processes, including proliferation, apoptosis, differentiation, and motility.  
The mammary gland begins development at approximately embryonic day 10.5, starts 
sprouting into the local mesenchyme at embryonic day 16, and continues isometric 
growth with elongation and branching until puberty begins at 3 weeks of age.  This 
rudimentary bud responds to the hormonal milieu of puberty by generating terminal end 
buds (TEBs), multilayered structures composed of body and cap cells. The TEBs invade 
the mammary fat pad using collective migration and provide the material for subtending 
ducts.  By 8-10 weeks, the TEBs have traversed the fat pad leaving in their wake an 
extensively branched mammary gland.  The fully developed gland contains ducts and 
acini lined with luminal epithelial and loosely encapsulated by basal myoepithelial cells.  
Proliferation, differentiation, and tissue remodeling during pregnancy and lactation are 
utilized to form alveolar clusters of milk producing cells.  Upon removal of pups, the 
mammary gland is reverted to a virgin-like state through involution, a process involving 
apoptosis and further tissue remodeling (reviewed in Cardiff and Wellings, 1999, in 
Hennighausen and Robinson, 2001, in Hennighausen and Robinson, 2005).  The dynamic 
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life cycle of the mammary gland is ideal for studying the processes involved in normal 
development and tissue homeostasis, as well as the processes that malfunction in cancer.  
Furthermore, most of the development of this non-essential organ occurs after birth 
allowing for ease of manipulation. 
 
Cadherins and mammary development 
 Cadherins are key players in mammary morphogenesis (reviewed in Knudsen and 
Wheelock, 2005 and in Andrews et al., 2012).  They are differentially expressed in the 
mammary gland with E- and P-cadherin being the most prominent version in body and 
cap cells of the TEB, respectively (Daniel et al., 1995).  This is echoed in the developed 
gland where E-cadherin is expressed in the luminal epithelial cells of ducts and acini, 
while P-cadherin predominates in the myoepithelial layers.  Addition of functional 
blocking antibodies against E- and P-cadherin to developing glands completely abolishes 
cell-cell adhesion and decreases cell proliferation of the body and cap cells, respectively.  
While these striking results indicate an essential role for both cadherins during pubertal 
development, interestingly, genetic E-cadherin ablation models give far more subtle 
outcomes.  Ablation of E-cadherin using a variety of different Cre-drivers leads to no 
effect on pubertal development, however null cells are also undetectable at this time point 
(Boussadia et al., 2002, Derksen et al., 2006, Derksen et al., 2011).  Some authors merely 
pass over this subtle finding to focus on the more pronounced findings at later stages 
(Boussadia et al., 2002).  Others conclude that E-cadherin ablation is not tolerated during 
development but do not explore it further (Derksen et al., 2006, Derksen et al., 2011).  
Without further examination of these mice, it is difficult to make solid conclusions about 
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the pubertal phase, however these data likely reflect selective pressures stemming from 
cell adhesion defects first observed in blocking antibody experiments.   
 Cadherin loss and misexpression also affect the lactation phase of mammary 
gland function.  During lactation, E-cadherin acts as a survival factor since knockout 
mice demonstrate early onset involution (Boussadia et al., 2002).  However, expression 
of the cytoplasmic domain of E-cadherin during lactation, which has a dominant-negative 
effect on adhesion, gives rise to the opposite effect: precocious alveolar formation 
(Delmas et al., 1999).  These findings, while seemingly contradictory, may highlight 
functions of the cytoplasmic domain (e.g. p120 binding and sequestration).  P-cadherin is 
also important for lactation as P-cadherin null females exhibit premature alveolar 
differentiation and develop hyperplasia when aged (Radice et al., 1997).  Finally, ectopic 
N-cadherin under the endogenous E-cadherin promoter exacerbates the precocious 
involution induced by E-cadherin ablation alone (Kotb et al., 2011).  Collectively, these 
studies suggest a vital role of cadherins during the mammary morphogenesis associated 
with lactation. 
 
Rho signaling and mammary development 
 Dynamic control of RhoA activity levels is essential for mammary gland 
development.  p190B RhoGTPase activating protein (GAP), a negative regulator of 
RhoA, is required for mammary gland morphogenesis and embryonic mammary bud 
formation (Chakravarty et al., 2003, Heckman et al., 2007). Overexpression of p190B 
Rho GAP results in increased branching, delayed ductal elongation, and tissue 
disorganization (Vargo-gogola et al., 2006).  p190A RhoGAP is also required for TEB 
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architecture and ductal outgrowth during puberty (Heckman-Stoddard et al., 2011).  Since 
both p190A and B RhoGAPs act to inhibit Rho activity, experiments with their absence 
suggest that hyperactive Rho signaling is incompatible with pubertal development.  
Interestingly, inhibition of Rho also blocks the processes necessary for branching 
morphogenesis (Ewald et al., 2008).  In an organotypic model, ROCK, a downstream 
RhoA target, is required for restoration of the epithelial bilayer and its inhibition impairs 
proper luminal and myoepithelial cell motility.  In this same system, Rac1 activation is 
required for duct initiation.  Collectively, these studies suggest that a proper balance and 
temporal regulation of Rho and Rac are necessary for mammary morphogenesis.  
 
p120 and its effectors in breast cancer 
 The American Cancer Society estimates that 229,060 new cases and 39,920 
deaths due to breast cancer will occur in 2012 alone (ACS, Facts and Figures, 2012).  
Worldwide, breast cancer is the most common malignancy among women, resulting in 
approximately half a million deaths a year due to metastatic disease.  Progression to 
metastasis, the main cause of mortality in patients, is achieved when cancer cells are 
capable of performing all steps of the metastatic cascade: local invasion; intravasation; 
survival in the circulation; extravasation; and colonization of the secondary site 
(Reviewed in Valastyan and Weinberg, 2011).  These acquired features of cancer cells 
are rooted in changes to cell-cell adhesion and survival and likely involve p120 and its 
effectors. 
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p120 in breast cancer 
 p120 is often dysregulated in human cancer (reviewed in Thoreson and Reynolds, 
2002).  Specifically in breast cancer, abnormal p120 levels and/or localization are 
commonly observed (i.e. range 69%-91% of cases) (Dillon et al., 1998, Nakopoulou et 
al., 2002, Sarrio et al., 2004, Paredes et al., 2008, Talvinen et al., 2010).  In ductal 
carcinoma, p120 downregulation is reproducibly observed in at least 50% of samples and 
regions of p120 loss are observed in approximately 10% of cases.  In a data set consisting 
of mostly invasive ductal cases, low p120 expression correlates with poor patient 
outcome (Talvinen et al., 2010).  These findings are mimicked in the MMTV-Polyoma 
Middle T (PyMT) mouse model of breast cancer wherein p120 is one of the most 
downregulated genes in the transition from adenoma to carcinoma (Kouros-Mehr et al., 
2008).  However, the relevance of these observations to ductal breast cancer progression 
has not been directly tested.  
 In lobular carcinoma, p120 is often cytoplasmic, reflecting the commonly 
occurring downregulation/silencing of E-cadherin that typifies this kind of breast cancer 
(Sarrio et al., 2004).  In fact, this mislocalization is so prevalent that it provides clinicians 
with a diagnostic tool to distinguish lobular from ductal carcinomas (Dabbs et al., 2007).  
Cytoplasmic localization of p120 is correlated with decreased overall survival (Paredes et 
al., 2008).  Recently, the contribution of this cytoplasmic pool to disease progression has 
been directly tested in a mouse model of lobular breast cancer (Derksen et al., 2006, 
Schackmann et al., 2011).  p120 is required for in vivo growth and metastasis because it 
facilitates resistance to detachment induced death, anoikis, in this model (Schackmann et 
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al., 2011).  Thus, the cytoplasmic pool of p120 observed in the pathology literature is 
truly part of the etiology of lobular breast cancer. 
 In contrast to ductal carcinoma, p120 is upregulated in Her2-driven and 
inflammatory breast cancer (IBC) (Landis et al., 2005, Silvera et al., 2009, Johnson et al., 
2010).  Upregulation of p120 mRNA is observed in the MMTV-neu mouse model and 
these findings are recapitulated when MCF10A cells are transformed with Neu (Landis et 
al., 2005, and Johnson et al., 2010).  p120 upregulation is proposed to activate Rac1 and 
Cdc42 downstream of src activation by Her2 and, ultimately, facilitate metastasis 
(Johnson et al., 2010).  As described above, IRES-dependent translation leads to 
upregulation of p120 in IBC (Silvera et al., 2009). Survival of IBC emboli in the 
lymphatic system requires upregulation of p120 (and subsequent stabilization of E-
cadherin) that is the direct result of IRES-dependent translation of p120 mRNA.  These 
latest findings specifically contribute to the understanding of two specific types of breast 
cancer, however the mechanisms contained within these studies may be more globally 
applicable.  Clearly, p120 levels are differentially altered in specific types of breast 
cancer and the importance of these levels is under continued investigation.      
 
p120 effectors in breast cancer 
 E-cadherin is a widely accepted tumor and metastasis suppressor (Perl et al., 
1998, Derksen et al., 2006, reviewed in Birchmeier and Behrens 1994, in Jeanes et al., 
2008).  In lobular carcinoma, E-cadherin loss occurs in the vast majority of cases and is 
thought to occur through mutation or epigenetic silencing of CDH1 combined with loss 
of heterozygosity (Moll et al., 1993, Gamallo et al., 1993, De Leeuw et al., 1997, Vos et 
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al., 1997, Berx et al., 1998, Lehr et al., 2000, Palacios et al., 2003).  In a breast cancer 
mouse model, E-cadherin loss is a direct mediator of tumor formation and causes 
metastatic disease (Derksen et al., 2006).  Thus, E-cadherin, in this setting, is indeed a 
tumor and metastasis suppressor.  However, in ductal carcinomas, E-cadherin expression 
is maintained or modulated rather than silenced (Moll et al., 1993, Rasbridge et al., 1993, 
Dillon et al., 1998, Nakopoulou et al., 2002).  Generally, E-cadherin reduction is 
correlated with metastasis and poor patient outcome, however many studies did not 
observe this correlation and some even suggest the opposite (Lipponen et al., 1994, 
Siitonen et al., 1996, Maguire et al., 1997, Charpin et al., 1998, Tan et al., 1999, 
Asgeirsson et al., 2000, Heimann et al., 2000).   
 These discrepancies in the pathology literature carry over into the experimental 
world, where the necessity and function of E-cadherin during metastasis of breast cancer 
cells is also inconsistent.  Ectopic E-cadherin expression in E-cadherin-null breast cancer 
cells prevents invasion and metastasis (Vleminckx et al., 1991, Mbalaviele et al., 1996, 
Meiners et al., 1998).  Similarly, depletion of twist, a transcriptional repressor of E-
cadherin, in the highly metastatic 4T1 mouse mammary carcinoma cell line prevents 
pulmonary metastasis (Yang et al., 2004).  Taken together, these studies indicate that E-
cadherin is metastasis suppressor.  However, there is also strong evidence for a 
requirement for E-cadherin during metastases (Lou et al., 2008, Dykxhoorn et al., 2009, 
Silvera et al., 2009, Korpal et al, 2011).  Of the members of a commonly used isogenic 
panel of mammary carcinoma cell lines, only the line that highly expresses E-cadherin 
(i.e. 4T1 cells) is fully competent at metastasis (Lou et al., 2008).  Another member of 
this panel, 4T07 cells, which are typically unable to colonize the lung, become 
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colonization-competent when forced to express miR200, an inhibitor of the 
transcriptional repressor of E-cadherin, Zeb2 (Lou et al., 2008, Dykxhoorn et al., 2009). 
Thus, E-cadherin expression also conveys metastatic capacity.  Furthermore, recent 
attention has been paid to the role of collective invasion, a process that is cadherin-
dependent, on its contribution to cancer metastasis (Giampieri et al., 2009, reviewed in 
Friedl and Wolf, 2003, in Friedl, 2004, in Sahai, 2005).   
 These seemingly contradictory findings may reflect the need for cellular plasticity 
in ductal carcinoma to achieve metastases, rather than just the presence or absence of E-
cadherin.  By being adaptable and plastic, cancer cells are able to overcome the unique 
challenges presented to them at each stage of the metastatic cascade: local invasion; 
intravasation; survival in the circulation; extravasation; and colonization (reviewed in 
Friedl, 2004, in Valastyan and Weinberg, 2011).  While there are a variety of methods by 
which cancer cells invade the surrounding stroma (reviewed in Sahai, 2005, in Friedl and 
Wolf, 2003), one of the most discussed is epithelial-to-mesenchymal transition (EMT), 
whereby a carcinoma cell takes on the attributes of a mesenchymal cell (reviewed in 
Kalluri and Weinberg, 2009).  While the specific molecular changes associated with 
EMT are multifaceted and often debated, the gold standard alteration during EMT is 
reduction of E-cadherin, and this is often accompanied by switching to expression of 
mesenchymal cadherins (Wheelock et al., 2008).  EMT confers a variety of abilities to 
cancer cells including increased motility and invasion, stemness, resistance to 
chemotherapy, and immune evasion (reviewed in Micalizzi et al., 2010).  However, the 
reverse process, mesenchymal-to-epithelial transition (MET), may be required to 
complete the entire metastatic cascade (reviewed in Hugo et al., 2007).  MET provides 
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cancer cells with key signals which may be critical for overcoming anoikis, survival in 
the circulation, and growth at the secondary site (Reddy et al., 2005, Kang et al., 2007, 
Wells et al., 2008, Chao et al., 2010, Chao et al., 2012).  Thus, while E-cadherin 
depletion during EMT may facilitate early stages of the metastatic cascade, E-cadherin 
expression during MET may support later steps in the cascade. 
 Given their participation in EMT, the role of mesenchymal cadherins in breast 
cancer metastasis is an active area of study.  In contrast to E-cadherin, mesenchymal 
cadherins are not expressed in the normal mammary epithelium, however they are 
upregulated in human breast tumors and likely facilitate progression to metastasis 
(Niemann et al., 1999, Pishvaian et al., 1999, Hazan et al., 2000, Kim et al., 2000, Feltes 
et al., 2002, Nagi et al., 2005, Yanagisawa and Anastasiadis 2006, Hulit et al., 2007).  
Forced expression of N-cadherin in either human breast cancer cells or a mouse model of 
breast cancer leads to increased invasion in vitro and metastasis in vivo (Hazan et al., 
2000, Suyama et al., 2002, Hulit et al., 2007).  N-cadherin promotion of metastasis is 
thought to occur by two non-mutually exclusive mechanisms.  In one scenario, N-
cadherin expression facilitates carcinoma-stroma interactions and thus invasion (Hazan et 
al., 1997).  In another scenario, N-cadherin protects FGFR-1 from ligand-induced 
downregulation by physically interacting with this RTK.  This leads to activation of MAP 
kinase signaling and secretion of MMP9, thus providing a mechanism for the previously 
described phenotypes (Suyama et al., 2002, Hulit et al., 2007).  Thus, expression and 
stabilization of mesenchymal cadherins, such as N-cadherin, likely promote breast cancer 
metastasis.  
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 Another p120 effector, RhoA, is central to breast cancer progression and 
metastasis.  RhoA is not mutated in breast cancer (Moscow et al., 1994) but rather is 
overexpressed or hyperactivated (Fritz et al., 1999, 2002).  This overexpression likely 
directly effects breast cancer progression as expression of dominant-negative Rho in 
MTLn3 invasive breast cancer cells reduces circulating tumor cells and completely 
prevents pulmonary metastases (Bouzahzah et al., 2001).  As such, direct targeting of 
RhoGTPase is thought be a promising new breast cancer therapy, however the quest for 
such inhibitors without non-specific toxicity is thus far unsuccessful (reviewed in Sahai 
and Marshall 2002, in Berndt et al., 2011).  Intratumoral injections of siRNA against 
RhoA in pre-clinical models stunt tumor growth without the toxicity observed with other 
methods (e.g. prenyltransferase inhibitors) (Pille et al., 2005).  Thus, RhoA is directly 
involved in breast cancer progression and may be a target for future breast cancer 
therapies. 
 
Hypothesis 
 I hypothesize that p120 plays a critical role in mammary development and breast 
cancer progression.  Specifically, I propose that p120 coordinates cadherins and Rho 
GTPase signaling during the dynamic and complex process of mammary morphogenesis.  
During breast cancer, loss or dysfunction of p120 likely potentiates metastasis given its 
role as a stabilizer of metastasis suppressor, E-cadherin.  However, a strong argument can 
be made for the opposite outcome.  Since p120 facilitates pro-metastatic events (e.g. 
mesenchymal cadherin stabilization and collective invasion), its absence may in fact 
prevent metastasis.  Furthermore, p120 isoforms 1 and 3 have unequal effects on key 
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parts of metastasis (e.g. invasion).  Thus, whether p120 ablation will inhibit or promote 
metastasis is far less predictable than originally thought and will be directly addressed 
here.  The primary objective of my work is to test these hypotheses and more 
importantly, contribute an understanding of the relevance of the observed changes to 
p120 in human breast cancer  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animals 
To generate mammary-specific p120 KO mice, p120f/f mice were backcrossed onto an 
FVB/NJ background and crossed with MMTV-cre#7 obtained from Dr. Muller on an 
FVB background (Andrechek et al., 2000; Andrechek et al., 2005; Davis and Reynolds, 
2006).  p120 ablation in a mouse model of breast cancer was achieved by crossing the 
mammary-specific p120 KO mice with the MMTV-Polyoma Middle T (PyMT) model 
(Guy et al., 1992).  Kaiso loss in this model was accomplished by crossing the PyMT 
mice with a global Kaiso null mouse (Prokhortchouk et al., 2006).  Genotyping was 
accomplished as previously described (Andrechek et al., 2000; Davis and Reynolds, 
2006, Prokhortchouk et al., 2006). All experiments involving animals were approved by 
the Vanderbilt University Institutional Animal Care and Use Committee. 
 
Whole Mount Mammary Gland Analysis 
Inguinal mammary glands were fixed overnight in Carnoy’s II [1:3:6 glacial acetic acid: 
chloroform: ethanol] fixative and gradually rehydrated.  Glands were stained with 
carmine alum, washed, and dehydrated.  Clearing was performed using Histoclear 
(National diagnostics, Atlanta, Georgia, USA).  Whole mount images were acquired 
using an Olympus QColor 3TM digital camera and assessed using Metamorph software 
(Molecular Devices, Sunnyvale, California, USA).  To quantify outgrowth, the average 
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distance of the three longest ducts was measured relative to a line tangential to the nipple-
proximal face of the lymph node. Outgrowths beyond and before the lymph node were 
quantified with positive and negative values, respectively.  To quantify TEB area, the 
average area of the six largest TEBs per whole mount was obtained. For both 
assessments, glands from at least five mice per genotype were analyzed. 
 
Immunohistochemistry 
Immunostaining on tissue was performed as previously described (Davis and Reynolds, 
2006).   Briefly, tissues were fixed in 10% formalin.  Paraffin-embedded tissue sections 
were deparaffinized and rehydrated.  Antigen retrieval was performed by boiling slides in 
10 mM Sodium Citrate pH 6.0 for 10 minutes.  After blocking, slides were incubated in 
primary and secondary antibody overnight and for 2 hours, respectively.  All antibodies 
are listed in Table 2. Sections were mounted with Prolong Gold Antifade Mounting 
Medium (Invitrogen, Carlsbad, California, USA). Tissue processing and hematoxylin and 
eosin (H&E) staining was performed by the Vanderbilt Translational Pathology Shared 
Resource Core using standard techniques.  TUNEL staining was performed as per the 
manufacturer’s instructions with the following modification: antigen retrieval for 10 
minutes in proteinase K (Millipore, Danvers, Massachusetts, USA).  Staining was 
visualized using an Axioplan 2 microscope (Zeiss, Oberkochen, Germany).  Images were 
collected with either an Olympus QColor 3TM digital camera or a Hamamatsu Orca ER 
fluorescent camera and processed using MetaMorph software.  
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Cell culture and Manipulation of MCF10A cells 
CommaD-beta (CDβ) cells, a gift from Dr. Medina at Baylor University, were cultured as 
previously described (Zhan et al., 2008).  Primary mammary epithelial cells were isolated 
and cultured as previously described (Vaught et al., 2009).  NMuMG and Phoenix293 
cells were cultured in DMEM supplemented with antibiotics and 10% heat-inactivated 
fetal bovine serum.  MCF10A cells were cultured as previously described (Debnath et al., 
2003).  For MCF10A manipulation, pRetroSuper-puromycin vectors expressing shRNA 
against human p120 and pLZRS (neomycin) vectors expressing mouse p120 isoforms 1A 
or 3A were utilized to deplete or add back p120, respectively (Davis et. al, 2003). 
pLZRS-neomycin vector expressing mouse p120 isoform 3A Δarm1.CAAX was 
generated as previously described (Wildenberg et al. 2006).  Production virus for protein 
expression and shRNA expression was conducted in Phoenix293 cells as previously 
described (Ireton et al., 2002).  MCF10A cells were selected for expression of 
pRetroSuper and pLZRS constructs by addition of 2 µg/mL puromycin and 500 µg/mL 
G418, respectively.  After transduction and selection, monoclonal cell lines of MCF10A 
p120 shRNA cells were generated using limiting dilution.  For rescue experiments, clonal 
cell lines were transduced with empty vector or vectors expressing mouse p120 isoform 
1A, 3A, or 3A Δarm1.CAAX.   
 
Generation and Manipulation of PyMT-derived Cell Lines 
Tumor tissue (as indicated) was collected under sterile conditions, minced into 1mm size 
pieces, and incubated in digest media [DMEM:F12, 1% antibiotic/antimycotic, 100 
units/mL hyaluronidase, 3 mg/mL collagenase A, gentimicin] for 3-4 hours with agitation 
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at 37°C.  Cells were pelleted at 1000 RPM and washed 5 times in PBS supplemented 
with 5% adult bovine serum.  Fibroblasts were removed by resuspending the pellet in low 
serum media and plating the material on a sterile petri dish.  After 1 hour in the incubator, 
cells not attached to the dish were spun down and resuspended in full growth media 
[DMEM:F12, 5% adult bovine serum, insulin, progesterone, 17-b-estradiol, EGF, 1% 
antibiotic/antimycotic, gentimicin].  Cells were plated onto collagen-coated plates and 
allowed to adhere for 48 hours before media changing.  Cell lines were established by 
passaging cells at least 15 times prior to experimental use after which point they were 
grown in DMEM supplemented with 10% FBS.  A variety of lines were generated using 
this method and their tissue sources were as follows: 177 (primary tumor), 584.4 
(primary tumor), 783.4A (lung metastasis), 986M2 (lung metastasis).  To enrich for 
metastatic potential, cell line 584.4A was generated by isolating a single lung met the 
from orthotopic transplant of cell line 584.4 (originally derived from a primary tumor).  
The PyMT-derived cell lines were used in the following figures: 177 (Fig.25A-D); 
986M2 (poly Fig.25E,F&27); 783.4A (mono #1 Fig.25F); 584.4A (mono #2 
Fig.26,25,&27).  To generate matched cell lines with and without p120 or E-cadherin, 
lentiviral constructs expressing non-targeting shRNA (control), cre recombinase (p120 
KO), or shRNA against mouse E-cadherin (E-cad KD).  Infected cells were selected for 
by puromycin treatment.  To make clonal cell lines (“mono” as listed in figures), cells 
were plated at low density and single clones were selected by cloning cylinders.  After 
upsizing, clones were screened for expression of keratin 8, p120, and E-cadherin.  For 
Kaiso experiments, 17L3C cells, derived from PyMT tumors by Dr. B. Fingleton, were 
utilized.  Kaiso depletion was achieved by lentiviral infection with Sigma Mission 
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construct #1009, 1659, and 2352 expressing shRNA against mouse Kaiso.  Infected cells 
were selected for by puromycin treatment. 
 
Cell Immunofluorescence 
Cells were plated on glass coverslips and fixed in 3% paraformaldehyde for 30 minutes.  
After PBS washes, cells were permeabilized in PBS with 0.2% TritonX-100 for 5 
minutes.  After more PBS washes, non-specific binding was blocked using PBS with 3% 
nonfat milk.  Cells were incubated in primary antibody for 30 minutes, washed, and 
incubated in secondary antibody for 30 minutes.  After 3 PBS washes, nuclei were 
stained using Hoechst dye.  Coverslips were coated in ProLong gold (invitrogen) and 
mounted on glass slides. 
 
Wound Healing Assays 
MCF10A or PyMT-derived cells were plated to confluence and scratched with a P200 tip 
to generate the wound.  Cells were rinsed with PBS, covered in growth media, and 
imaged at 6 regions per scratch every 6 hours.   Cell migration was calculated as percent 
closure of the original wound.  For time-lapse microscopy, the above procedure was 
performed and cells were imaged every 10 minutes.  Images were acquired using an 
Axiovert 200M microscope (Zeiss) and processed using MetaMorph software. 
 
Western Blot Analysis 
Protein was isolated as previously described (Mariner et al., 2004).  Briefly, cells were 
washed with PBS, lysed in RIPA buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1% 
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Nonidet P-40, 0.5% Deoxycholic Acid, 0.1% sodium dodecyl sulfate] containing 
inhibitors [1mM phenylmethylsulfonyl fluoride, 5 µg/mL leupeptin, 2 µg/mL aprotinin, 
1mM sodium orthovanadate, 1mM EDTA, 50mM NaF, 40mM B-glycerophasphate] and 
spun at 14,000g at 4°C for 5 minutes.  Cleared total protein was quantified using a 
bicinchoninic acid assay (Pierce, Rockford, Illinois, USA).  20 µg of protein per sample 
were boiled in 2X laemmli sample buffer and separated by SDS-polyacrlamide gel 
electrophoresis.  Proteins were transferred to nitrocellulose (PerkinElmer, Waltham, 
Massachusetts, USA).  Non-specific binding was blocked by incubating membranes in 
3% nonfat milk in Tris-buffered saline and odyssesy blocking buffer (LI-COR, Lincoln, 
Nebraska USA) prior to addition of primary and secondary antibodies, respectively.  
Anti-p120/pp120 (0.1µg/mL, BD Biosciences), anti-E-cadherin (0.1µg/mL, BD 
Biosciences), anti-tubulin/DM1α (1:1000, Sigma-Aldrich), anti-N-cadherin (0.8µg/mL 
13A9, Millipore), and anti-P-cadherin (1:250, BD Biosciences) antibodies were used.  
The odyssey system was used for detection of secondary goat anti-mouse IgG IRDye 
800CW antibodies (1:10,000 LI-COR).  
 
3D Branching Assays and Mammary Transplants 
Primary Mammary Epithelial Cells (PMECs) were isolated as previously described 
(McCaffrey and Macara 2009).  Lentivirus was generated by transfecting HEK293T cells 
with pLL5.0-GFP expressing shRNA against human (control) or mouse p120 (p120i) and 
psPAX2 and pMD2.G (Addgene).  PMECs were infected with lentivirus (MOI=100) for 
3 hours during centrifugation at 300g.  Cells were grown in suspension on low adhesion 
plates (Corning) for 5-7 days in mammosphere media (DMEM:F12; 20 ng/mL EGF, 20 
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ng/mL FGF2, and 2% B27 supplement) (Dontu et al. 2003).  For 3D branching assays, 
100 mammospheres were suspended in 50 µL Matrigel per 96-well plate well and 
equilibrated in minimal media (DMEM:F12, 1% v/v insulin/transferring/selenium, 1% 
penicillin/streptomycin)(Ewald et al. 2008).  Branching was induced with 2.5 nM FGF2 
in minimal media changed twice.  Quantification of percent branched and number and 
fluorescence status of branches was performed after 7 days (>30 mammospheres per 
experiment).  For mammary transplantation assays, PMECs were infected and grown in 
suspension.  After 7 days, cells were trypsinized and flow sorted for GFP by the 
Vanderbilt Flow Cytometry Laboratory.  1x105 cells in 10 µL of PBS with 10% Matrigel 
expressing control GFP or p120i GFP virus were injected into contralateral cleared fat 
pads of 3-week-old FVB mice.  After 6 weeks, glands were removed and analyzed for 
GFP positive outgrowth relative to gland size using a Nikon AZ 100M fluorescent 
widefield microscope. 
 
Tail Vein Injections and Lung Whole Mount 
PyMT-derived cells were trypsinized and pelleted at 1000g.  After 2-3 washes in PBS, 
cells were passed through a 70 µM pore cell strainer.  1x106 cells per 100 µL were 
injected into the tail vein of mice.  After 4 weeks, mice were sacrificed and lungs were 
collected.  Lungs were analyzed by whole mount and tumor burden analysis.  Tumor 
burden was quantified as a percent of metastases area to total lung area at 3 depths per 
lung.  For lung whole mount, lungs were inflated with formalin and fixed overnight.  
Lungs were then dehydrated in progressive increasing amounts of ethanol and cleared 
overnight in Histoclear.  Rehydration the next day was followed by staining in Mayer’s 
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hematoxylin.  After destain steps in 1% HCl solution and water, lungs were dehydrated 
and cleared once again.  Analysis of lung metastases was performed using a dissecting 
scope and an Olympus QColor 3TM digital camera.  
 
Transwell Invasion Assays 
Matrigel-coated transwells were equilibrated by the manufacturer’s instructions.  Cells 
were then plated in serum free media in the top well and promoted to invade toward 10% 
media in the bottom chamber.  After 24-48 hours, transwells were fixed and stained using 
a Diff-Quik staining kit (Allegiance).  10 random fields of view per transwell were 
analyzed. 
 
Macrophage Invasion Assays 
Intraperitoneal injections with 2 mL thioglycolate were performed using a 27G needle.  
After 4 days, the abdominal cavity was filled with PBS and peritoneal macrophages were 
isolated.  Cells were pelleted and resuspended in serum free media and immediately used 
for invasion assays as described above.  To generate the stimulus for macrophage 
invasion, PyMT-derived cells were grown in 3D matrigel cultures for at least 7 days.  
Serum free media was added to the cultures and collected after 24 hours.  This media was 
then used for invasion induction of macrophages.  
 
Whole Tumor and Spleen Flow Cytometry 
Tumors were collected, minced, and incubated in digest media [RPMI with 1 mg/mL 
collagenase I, 1 mg/mL dispase II] for 2 hours at 37°C.  Tumor material was then pressed 
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through a 70 µM cell strainer in 10 mL cold PBS and repeated for a total of 50 mL PBS. 
Tumor cells were then treated with 10 µL of 5MU/mL DNAseI for 5 minutes at room 
temperature.  Cells were pelleted at 300g to remove DNAse treatment.  Spleens were 
minced and pressed through a 70 µM cell strainer in 10 mL cold PBS and repeated for a 
total of 50 mL PBS.  Red blood cells were removed from tumor and spleen preparations 
using lysis buffer.  Cells were washed with PBS, strained, and then counted in the 
presence of trypan blue.  Each sample of 5x10^6 cells per 100 µL flow buffer [PBS, 0.5% 
BSA, 2mM EDTA] was treated with Fc block and then incubated in antibodies 
conjugated to compatible fluorophore combinations for 30 minutes on ice.  All antibodies 
were purchased through eBioscience.  Antibodies combinations are listed in Table 3.  
After 2 washes with flow buffer, cells were analyzed by flow cytometry by the 
Vanderbilt Flow Cytometry Shared Resource Core.    
 
Anchorage Independent and 3D Matrigel Growth 
For anchorage independent growth assays, 6 well-dishes were coated with a bottom layer 
of 0.7% low gelling temperature agarose.  5x10^3 PyMT-derived cells suspended in 
0.35% agarose were plated per well and covered in 2 mL growth media.  After 3.5 weeks 
of growth, colonies were imaged using an inverted microscope.  For 3D growth assays, 
35 mm tissue culture dishes were coated with 500 µL of Matrigel.  7x10^5 PyMT-derived 
cells were plated in growth media supplemented with 2% Matrigel.  
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Cytokine Arrays and Microarrays 
PyMT-derived cells were grown in 3D matrigel as described above.  For cytokine arrays, 
cultures were rinsed once with serum free media and secreted factors allowed to 
accumulate in serum free media overnight.  Secreted media collected from 9 and 19 day 
control and p120 KO cultures was added to the RayBio Mouse G3 Cytokine Array.  
Arrays were performed as per the manufacturer’s instructions.  For microarrays, total 
RNA was isolated using RNAStat60 (Amsbio) and RNeasy Mini Kit (Qiagen).  RNA was 
hybridized to Affymetrix Mouse Gene 1.1 ST arrays.  Targets changed consistently at 
least 1.6 fold over control in each sample were considered meaningful.  Analysis for 
cytokine arrays and microarrays was performed with assistance by the Functional 
Genomics Shared Resource Core. 
 
Contractility Assays 
Contractility assays were performed as extensively described by Wozniak and Keely 
(Wozniak and Keely, 2005).  Briefly, 1X10^5 cells were suspended in 1 mL of 1:1 type I 
collagen (1.19 mg/mL final concentration) to neutralization solution [100mM Hepes in 
2X PBS pH 7.3]. 1 mL was added per 6-well and each cell line was plated in triplicate.  
After overnight incubation, gels were floated using a P200 tip.  Two days post floating, 
gel contraction was measured for each cell type. 
 
Orthotopic Transplant 
1X0^6 cells were suspended in 50 µL of 1:1 type I collagen (1.19 mg/mL final 
concentration) to neutralization solution [100mM Hepes in 2X PBS pH 7.3].  Plugs were 
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allowed to solidify for 1 hour in the incubator and then covered in growth media.  The 
following day plugs were transplanted into the cleared fat mammary fat pads of mice. 
 
qRT-PCR on Macrophages 
Total RNA was extracted from sorted CD45+CD11b+F4/80+ cells from tumors of d54 
PyMT control and p120 KO mice (n=3 per genotype) using QIAshredder columns and 
RNeasy mini kit (Qiagen). cDNA was synthesized using Invitrogen Superscript First-
strand synthesis system for RT-PCR (Invitrogen).  Primers specific for iNOS, TNFα, IL-
12, IL-6, IL-1b, VEGF, MMP2, MMP9, MMP13, CXCL1, and IL-10 were used and the 
relative gene expression was determined using ABI PRISM 7900HT Sequence Detection 
System (PE Applied Biosystems).  The comparative threshold cycle method was used to 
calculate gene expression normalized to β–actin. 
 
Circulating Tumor Cell Colonization Assay 
Mice 54 days after initial palpation were euthanized (n=4 per genotype) and whole blood 
was collected in a heparinized needle.  Each well of a 6-well dish was coated in 1:1 mix 
of matrigel and DMEM supplemented with 10% FBS.  After Matrigel solidification, 500 
µL of whole blood was plated per 6-well dish and covered in 2 mL media.  After 48 
hours, cultures were washed with PBS.  Red blood cells were removed with lysis buffer 
[155 mM NH4Cl, 12mM NaHCO3, 0.1 mM EDTA] and then washed away with PBS.  
Colonies were then allowed to grow for 7-10 days with media changes every 3-4 days. 
Colonies were counted in 5 random 2.5x fields and 10 random 10x fields.   
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Statistical Analysis 
Statistical analyses were preformed using Prism (GraphPad La Jolla, California, USA) as 
described in figure legends.  For assays with or without normal distribution, two-tailed 
Student’s t-tests or Mann-Whitney tests were performed, respectively.   
 
 
 
 49 
CHAPTER III 
 
 
P120-CATENIN IS ESSENTIAL FOR TERMINAL END BUD FUNCTION AND 
MAMMARY MORPHOGENESIS 
 
 
 
Introduction 
Cell-cell adhesion plays a key role in development, tissue maintenance and cancer 
(Birchmeier, 1995; Gumbiner, 2005; Takeichi, 1995; Yap, 1998).  In vertebrates, the 
classical cadherins (i.e., Type I and Type II cadherins) comprise a large family (26 
members) of transmembrane glycoproteins found in essentially all adhesive tissues 
(Gallin, 1998; Hulpiau and van Roy, 2009).  Epithelial-cadherin (E-cadherin) is the main 
cadherin in epithelial tissues and plays an important role in morphogenesis and 
homeostasis in most glandular tissues, including the mammary gland.  Although the 
importance of cadherins in mammary morphogenesis is widely accepted, the role of p120 
catenin in this process remains to be investigated.   
The extracellular domains of cadherins connect adjacent cells via homophillic 
interaction, while the cytoplasmic domains form a complex with a group of proteins, 
known as catenins (Gumbiner, 2005; Takeichi, 1991). p120-catenin (hereafter p120) and 
β-catenin are armadillo repeat domain proteins that bind directly to distinct regions of the 
cytoplasmic domain (Davis et al., 2003; Hulsken et al., 1994; Ireton et al., 2002; McCrea 
and Gumbiner, 1991; Reynolds et al., 1996; Takeichi et al., 1989; Thoreson et al., 2000; 
Yap et al., 1998). β-catenin connects the cadherins physically and/or functionally to the 
actin cytoskeleton through a mechanism involving α-catenin (Herrenknecht et al., 1991; 
Nagafuchi et al., 1991; Rimm et al., 1995; Yamada et al., 2005).  In contrast, p120 
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appears to regulate the strength of cell-cell adhesion by modulating cadherin retention at 
the cell surface (Davis et al., 2003; Ireton et al., 2002; Xiao et al., 2003).  In its absence, 
cadherins are internalized and degraded, thus defining p120 as a master regulator of 
cadherin stability (Davis et al., 2003).  p120 is also thought to modulate actin dynamics 
via Rho-GTPases, -GEFs, and GAPs (Anastasiadis et al., 2000; Noren et al., 2000; 
Wildenberg et al., 2006).  Together, these observations suggest that the catenins play a 
central role in regulating functional interactions between cadherins and the actin 
cytoskeleton.  
Phenotypes associated with p120 ablation in vivo appear to be largely tissue 
dependent and surprisingly unpredictable (Bartlett et al., 2010; Davis and Reynolds, 
2006; Elia et al., 2006; Marciano et al., 2011; Oas et al., 2010; Perez-Moreno et al., 2006; 
Smalley-Freed et al., 2010; Stairs et al., 2011).  For example, in the developing salivary 
gland, p120 ablation completely blocks acini formation (Davis and Reynolds, 2006).  
Ducts are grossly distorted and characterized by cell-cell adhesion defects reminiscent of 
those observed in intraepithelial neoplasia. On the other hand, p120 knockout (KO) in the 
epidermis induces a massive inflammatory response despite essentially normal adhesion 
and barrier function (Perez-Moreno et al., 2006). In the intestine, p120 KO causes a 
prominent barrier defect along with cell-cell adhesion abnormalities and inflammation 
(Smalley-Freed et al., 2010). These animals die from gastrointestinal bleeding within 3 
weeks of birth. Other p120 KO-associated defects include reduced vessel density and 
anomalies in dendritic spine and synapse development in hippocampal neurons (Elia et 
al., 2006; Oas et al., 2010). Surprisingly, p120 KO in the prostate has no detectable effect 
on either cell morphology or adhesion despite near complete downregulation of E-
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cadherin (A.B. Reynolds, unpublished). These studies, for the most part, reflect dramatic 
phenotypes, although consequences of p120 ablation differ markedly from one organ 
system to the next.  However, the effects of p120 loss in the mammary gland have not 
been formally addressed. 
The mammary gland provides an outstanding in vivo system for studying 
morphogenetic events (e.g. invasion and differentiation), since the majority of the 
development of this non-vital organ occurs after birth.  Prior to puberty, the mammary 
gland exists as a rudimentary ductal tree.  At the onset of puberty around 3 weeks of age, 
proliferative structures at the tips of ducts, known as terminal end buds (TEBs), develop 
and begin to invade the surrounding stroma (Hinck and Silberstein, 2005). TEBs are 
comprised of a dynamic mass of E-cadherin positive luminal body cells surrounded by a 
motile cap cell layer expressing P-cadherin (Daniel et al., 1995; Ewald et al., 2008; Hinck 
and Silberstein, 2005).  The TEBs bifurcate repeatedly to form the ductal tree and 
ultimately, the mature gland.  This process, termed branching morphogenesis, concludes 
around weeks 10-12 when the TEBs have traversed the length of the fat pad and a fully 
developed ductal tree has formed (Cardiff and Wellings, 1999; Hennighausen and 
Robinson, 2005; Richert et al., 2000; Sternlicht, 2006).  Disruption of TEBs is often 
associated with delayed ductal outgrowth and impaired branching morphogenesis thus 
suggesting an essential function of TEBs in the overall development of the mammary 
gland (Jackson-Fisher et al., 2004; Kouros-Mehr et al., 2006; Lu et al., 2008; Parsa et al., 
2008; Srinivasan et al., 2003; Sternlicht et al., 2006).  
Here, we examine the role of p120 in the developing mammary epithelium. 
MMTV promoter-driven Cre recombinase expression in p120f/f mice was used to induce 
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p120 ablation at the onset of puberty.  In week 4, developing epithelial structures 
exhibited mosaic p120 ablation, the extent of which varied widely between mice.  p120 
loss in nascent ducts caused severe morphological defects (e.g. cell rounding and 
sloughing into the lumen), despite the presence of family members, which were unable to 
compensate for p120 loss.  p120 null cells were observed less frequently in the TEB itself 
due to rapid shedding from TEBs.  In vitro two- and three-dimensional modeling suggest 
that TEB function is compromised in the absence of p120, most likely due to defects in 
cell-cell adhesion and collective cell migration.  At the whole organ level the phenotype 
manifested as a transient delay in ductal outgrowth due to selective loss of p120-null cells 
and preferential outgrowth of the p120-positive cell population. Reconstitution with pure 
populations of p120-depleted cells blocked mammary gland formation completely. These 
data reveal an essential, non-redundant role for p120 in mammary gland development.  
Results 
Characterization of p120 expression in the developing mammary gland  
To characterize baseline p120 expression patterns in the developing mammary 
gland, sections of glands from 4-week-old control mice were co-immunostained with 
antibodies to p120 along with the basal and luminal cell markers smooth muscle actin 
(SMA) and keratin 8 (K8), respectively (Fig.5A).  Figure 5A illustrates diffuse p120 
staining of stromal cells (arrows) and sharp junctional staining in the epithelium of ducts 
(top panels) and terminal end buds (TEBs) (bottom panels).  Note that p120 staining in 
the basal compartment of the TEB is markedly reduced relative to the very strong 
staining in the luminal compartment.  These patterns of p120 localization were the same 
over all stages of pubertal development (data not shown).   
Figure 5. p120 is ubiquitously expressed in the mouse mammary gland
(A) Immunostaining for p120, SMA, and K8 on sections from glands of 4 
week-old females.  SMA and K8 mark the cap and body cells, respectively.  
Representative images for ducts and terminal end buds (TEB) are shown.  
Arrow denotes diffuse stromal p120 staining.  Dotted line indicates the divi-
sion between body and cap cells.  Scale bar = 50 μM. (B) Immunoblots for 
p120 and tubulin in a panel of normal mammary epithelial cells. (C) Diagram 
of the mammary TEB and duct. 
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Typically, epithelial cells predominantly express p120 isoform 3, whereas 
fibroblasts express isoform 1.  However, figure 5B illustrates biochemically that primary 
mammary epithelial cells (PMECs) and the untransformed mouse mammary cell lines 
CDβ and NMuMG express both p120 isoforms 1 and 3.  Furthermore, both layers of the 
mammary epithelium demonstrated positive immunostaining using an antibody that only 
recognizes p120 isoform 1 and 2 suggesting that isoforms other than 3 are also expressed 
in the epithelium in vivo  (data not shown).  Collectively, these results demonstrate 
expression of p120 in the mature basal and luminal mammary epithelium, as well as in 
the body and cap layers of the TEB.  
 
Mosaic p120 knockout at puberty induces transient delay of ductal outgrowth 
To target p120 knockout to the mammary gland, MMTV-Cre;p120fl/fl mice were 
generated by crossing MMTV-Cre #7 mice on an FVB background (Andrechek et al., 
2000; Andrechek et al., 2005) to floxed p120 mice, which was backcrossed to a FVB 
background (Davis and Reynolds, 2006).  Effects of p120 ablation were examined 
initially by whole mount analysis at time points spanning pubertal development (Fig.6).  
At 3 weeks, knockout and control rudimentary mammary trees were grossly 
indistinguishable (Fig.6A).  In contrast, ductal outgrowth was significantly reduced at 
weeks 4, 5, and 6 (Fig.6A,2B).  By week 9, however, control and knockout glands were 
again indistinguishable.  Thus, p120 ablation induces a transient delay in ductal 
outgrowth that is ultimately resolved by week 9.   
Further analysis of the glands by immunostaining revealed mosaic, epithelium-
specific p120 ablation in all experimental animals starting at week 3. Significant p120 
Figure 6. p120 ablation in the developing mammary gland 
delays ductal outgrowth 
(A) Images of virgin mammary gland whole mounts from control and p120 KO 
animals. LN denotes lymph node. Scale bars = 1 mm (B) Quantitative com-
parisons of ductal outgrowth. Graph depicts mean and s.e.m. Mann-Whitney 
test *p<0.05.   (C) Representative images of immunostaining for p120 in 
4-week-old glands.  Arrowheads denote areas of knockout.  Scale bar = 50 μ
M. (D) Quantification of p120 ablation in glands from mice at indicated ages. 
Graph depicts mean and s.e.m. Mann-Whitney *p<0.05. (E) Representative 
images for p120 and K8 of glands at indicated ages.  Scale bar = 50 μM.
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 knockout was observed at week 4 (Fig.6C).  The overall percentage of knockout cells 
varied widely (range: 38-6.7%, n=6) but averaged 22% of the nascent epithelium 
following puberty-induced expression of Cre (Fig.6D,E). Thereafter, p120 null cells were 
increasingly scarce and almost completely absent by week 6 (range: 0-0.9% n=5) 
(Fig.6D,E).  Thus, from week 6 on, glands were essentially p120 positive (despite the 
MMTV-Cre;p120fl/fl genotype) and further development (including pregnancy and 
lactation) was indistinguishable from that of p120fl/fl controls.  
The rapid loss of p120 null cells between weeks 3 and 6 suggested the possibility 
of reduced cell proliferation or elevated cell death.  We broadly assessed cell death by 
TUNEL staining, which marks cells undergoing apoptosis, necrosis, or lysosome-
mediated death (Grasl-Kraupp et al., 1995; McIlroy et al., 2000; Overholtzer et al., 2007).    
There was no statistically significant change in global cell death in p120 KO ducts or 
TEBs (Fig.7A,B a-b).  However, the percent of cells TUNEL positive increased 3-fold 
when analyzing only those detached from the body of the TEB in knockout mice 
(Fig.7A,B a-b arrows).  Similarly, detached cells demonstrated a 4-fold increase in the 
percent positive for cleaved caspase 3 further suggesting that p120 null cells are dying by 
anoikis, detachment-induced cell death (Fig.7AB, c-d arrows).  This cell detachment was 
rarely seen in control TEBs.  Cell proliferation in ducts and TEBs was unaffected by 
p120 ablation as monitored by phosphorylated histone H3 staining (Fig.7A,B e-f).   
We also examined the possibility that p120-null cells might be removed or 
engulfed by elements of the immune system.  In several other organ systems (e.g., 
intestine, esophagus, epidermis), p120 ablation is associated with significant immune cell 
infiltration, which could facilitate rapid clearance of malfunctioning cells.  However, 
Figure 7. Analysis of proliferation and cell death in the absence of p120
Analysis of cell death and proliferation was performed on ducts (A) and TEBs 
(B). (a-b) Representative TUNEL stained sections from glands of 4-week-old 
control and p120 knockout mice.  Arrows denote detached TUNEL positive 
cells.  (c-f) Analysis of apoptosis and proliferation was performed using immu-
nostaining for cleaved caspase-3 (c-d) and phosphorylated histone H3 (e-f), 
respectively.  Values are mean +/- s.e.m. and n= number of animals. D denotes 
analysis of detached cells.  Student’s t-test *p<0.05.  All scale bars = 50 μM.
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 immunostaining for macrophage/eosinophil- (anti-F4/80) and neutrophil- (anti-Ly-6B.2) 
markers showed little, if any, evidence for unusual recruitment of these cell types (data 
not shown).  Collectively, these experiments suggest that p120 null cells are being 
selectively lost by anoikis and subsequent clearance by mechanisms that do not involve 
obvious inflammation.  
 
p120 is required and non-redundant for ductal architecture 
To determine the immediate consequences of p120 loss on ductal architecture, 
sections from week 4 glands were analyzed by hematoxylin and eosin (H&E) staining 
and immunofluorescence microscopy (Fig.8).  H&E analyses revealed cell-cell adhesion 
defects manifested by dramatic cell sloughing and frequent partial occlusions of the 
lumens (Fig.8A).  Immunostaining for the apical marker Crumbs 3 illustrated obvious 
rounding of the apical cell surface, presumably reflecting poor basolateral cell-cell 
adhesions (Fig.8B).  On the other hand, basal cells (marked by p63) were never displaced 
from their normal position at the basement membrane, but appeared more sparse than in 
the wildtype glands (Fig.8C).  
As observed in several other organ systems, p120 ablation selectively affected the 
adherens junction as shown by decreased expression of E-cadherin and β-catenin in p120 
null cells (Fig.9A,B).  Loss of p120 did not affect ZO-1 expressing tight junctions 
(Fig.9C) or desmosomes (data not shown).  Since immunostaining of E-cadherin and β-
catenin was dramatically decreased in the absence of p120, these data suggest that p120 
family members, if present, are unable to compensate in this tissue.  Therefore, we 
analyzed the expression of p120 family members, ARVCF, p0071, and δ-catenin, using 
Figure 8. p120 ablation disrupts ductal architecture
(A) Serial sections of mammary glands from 4 week-old mice were stained 
with H&E and with antibodies against p120.  Representative images of the 
two phenotypes observed, luminal sloughing and partial occlusions, are 
shown.  Arrow denotes sloughed knockout cells.  (B) 4-week-old glands were 
co-immunostained for p120 and Crumbs3.  Arrows indicate the mislocalized 
apical marker and severe disruption ductal morphology in areas of p120 
ablation. (C) 4-week-old glands were co-immunostained for p120 and p63.  All 
scale bars = 50 μM.
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Figure 9. Dysregulation of the mammary gland cadherin complexes 
in the absence of p120
Sections of mammary glands from control and p120 knockout mice were 
co-immunostained for the following: (A) p120 and E-cadherin; (B) p120 and 
β-catenin; (C) p120 and ZO-1.  Dotted circles denote areas of p120 ablation 
and consequent downregulation of E-cadherin and β-catenin, but not ZO-1.  All 
scale bars = 50 μM.
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 well-characterized antibodies (Hofmann et al. 2009, Marciano et al. 2011, Walter et al. 
2008, Walter et al. 2010).  Family members demonstrated membranous and cytoplasmic 
localization in the mammary epithelium, which was not altered in the absence of p120 
(Fig.10).  Thus, p120 provides a non-redundant function in cell-cell adhesion of 
mammary ductal cells.  
 
p120 null cells are rapidly sorted and eliminated from nascent TEBs  
The driving force behind development of the mammary gland during puberty is 
the TEB, where the vast majority of cell growth, death, and invasion occur.  To determine 
the role of p120 in the TEB, we examined the effects of p120 ablation on TEB size and 
morphology (Fig.11).  While total TEB number was not altered in p120 knockout mice 
(data not shown), average TEB size was significantly reduced at week 4 (Fig.11A,B). 
However, TEB size normalized by week 5, well before the knockout gland outgrowth 
caught up with that of the wildtype gland (Fig.11A,B and Fig.6).  Thus, the early delay in 
ductal elongation due to p120 ablation may occur in response to events taking place with 
the TEBs, which rely on p120 expression.  
To understand the nature of the defect at week 4, the histological morphology of 
TEBs from 4 week-old mice was examined.  Figures 11C & 11D show examples of 
typical TEB phenotypes in cross and longitudinal sections, respectively.  Interestingly, 
the majority of TEBs from KO mice lacked p120 null cells altogether, suggesting that the 
early size discrepancy might reflect very rapid clearing and/or loss of p120 null cells 
from these structures. In TEBs retaining significant numbers of p120 null cells, the cells 
invariably were rounded, non-adhesive, and likely unable to participate in endbud  
Figure 10. p120 family members cannot compensate for p120 loss.
Sections from mammary glands of 4-week-old control and p120 knockout 
mice were co-immunostained with antibodies against p120 and ARVCF (A) or 
δ-catenin (B) or p0071 (C).  Dotted regions denote areas of p120 ablation.  
Scale bar = 50 μM.
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Figure 11. p120 null cells are rapidly shed and fail to 
participate in TEB development.
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Figure 11. p120 null cells are rapidly shed and 
fail to participate in TEB development.
 (A) Whole mount images of control and p120 knockout mammary glands. LN 
denotes the lymph node. Dotted circles highlight representative TEBs.  Scale 
bars = 1 mm (B) Analysis of TEB size.  Knockout mice exhibited statistically 
significant decrease in TEB size at 4 weeks but not 5 weeks of age.  Graph 
depicts mean and s.e.m.  Student’s t-test *p<0.05. (C) Cross-sections of TEBs 
from inguinal mammary glands harvested at 4 weeks.  Serial sections were 
stained with H&E (a, d, g) or immunostained for p120, SMA, and K8.  Nuclei 
were costained with Hoechst dye.  Examples of luminal (d-f) and subcapsular 
(g-i) sloughing are shown. All scale bars = 50 μM. (D) Longitudinal sections of 
TEBs from inguinal mammary glands harvested at 4 weeks.  Sections were 
immunostained for p120 and E-cadherin. Examples show luminal (top) and 
subcapsular (bottom) cell sloughing. All scale bars = 50 μM.
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activity.  In general, such structures segregated into one of two distinct scenarios based 
on where the p120 null cells accumulated.  Figure 11C (d-f) illustrates sloughing of p120 
null cells to the lumen. Alternatively, TEBs from p120 KO mice frequently contained 
aberrantly large subcapsular spaces, and these also were found to accumulate significant 
numbers of p120 null cells (Fig.11C g-i).  The presence of p120 family members was 
insufficient to support TEB morphology in the absence of p120 (data not shown).  
To identify the origin of the sloughed p120 null cells (i.e. cap versus body cells), 
we analyzed the images for basal (SMA) or luminal (K8) markers (Fig.11C).  Cross-
section of TEBs from control mice demonstrated a multi-layered, K8+/p120+ body, 
surrounded by a single-cell SMA+ cap cell layer, that also expressed p120, albeit at lower 
levels (Fig.11C).  p120 null cells shed into the lumen were K8+/SMA- (Fig.11Cf arrow).  
Whereas, p120 null cells accumulating in the subcapsular compartment were 
predominantly K8-/SMA+ suggesting that they were derived from the cap layer or 
myoepithelial cells (Fig.11Ci arrowhead).  Occasional examples of K8+/SMA-/p120- 
cells were detected in the subcapsular region (Fig.11Ci arrow).  Note that p120 
expressing cells were rarely seen in the lumen or in the subcapsular space.  Similar results 
were observed in longitudinal TEB sections stained with antibodies against p120 and E-
cadherin (Fig.11D).  Together, these observations show that p120 null mammary 
epithelial cells generated at puberty in the nascent TEBs were derived from both body 
and cap cell components, underscoring the requirement for p120 in both epithelial cell 
populations for adhesion and TEB morphogenesis.   
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p120 loss in vitro disables collective migration required for branching morphogenesis in 
vivo 
To clarify mechanism, we utilized RNA interference to stably knock down p120 
in the nontumorigenic human mammary cell line, MCF10A (Fig.12).  Although 
experiments in vitro do not necessarily recapitulate the complexity of in vivo 
morphogenesis, MCF10A cells have nonetheless been used frequently for mechanistic 
modeling of collective migration and other phenomena associated with mammary 
development (Debnath et al., 2002; Simpson et al., 2008). Figure 12A illustrates the 
extent of p120 knockdown in two independently derived MCF10A clones. Similar to 
what was seen in the mammary epithelium, E-cadherin levels are significantly reduced by 
p120 depletion and efficiently rescued by forced expression of either p120 isoform 1A or 
3A (Fig.12A).  
In 2D cell cultures, parental MCF10A cells formed tightly adherent colonies, 
whereas cell-cell adhesion was completely disrupted by p120 knockdown (Fig.12B).  The 
phenotype was efficiently rescued by either p120 isoform 1A or 3A, as expected if the 
cell-cell adhesion defects are the result of p120 depletion (Fig.12B).  
We then examined the effects of p120 depletion on 3D acinar morphogenesis 
using a previously described matrigel system (Fig.13) (Debnath et al., 2003). While 
parental MCF10A cells formed simple lumen-containing acini, loss p120 resulted in 
disorganization of acinar structure and poorly defined lumens (Fig.13).  In general, these 
structures closely resembled the images of p120 null ducts illustrated in figure 8.   
Collective cell migration is required for TEB invasion through the mammary fat 
pad.  To assess the role of p120 in collective cell migration, we conducted p120 
Figure 12. p120 is required for collective migration
(A) Lysates from parental MCF10A cells, p120 knockdown monoclonal lines 
(p120i 1 and 2) and polyclonal cells expressing control, human p120 isoform 
1A, or 3A vectors were analyzed by immunoblotting as indicated (tubulin 
loading control). (B) 2D morphology. Subconfluent cells were imaged by 
bright field microscopy (C) Wound healing assays. Images are from time-
lapse videos using indicated cell lines. Scale bar = 50 μM.  Arrows denote 
single cell migration events. (D) Quantification of wound healing.  Cells from 
(A) were assayed at 6 or 12 hours.  Graph depicts mean and s.e.m. of 5 
independent experiments. Mann-Whitney tests: *p<0.05 compared to paren-
tal MCF10A cells and #p<0.05 compared to p120i+empty vector.  
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Figure 13. 3D morphology of p120-depeleted MCF10A cells is disrupted
(A) MCF10A cells were grown as mammospheres as described in the 
methods and imaged using bright field microscopy after 12 days. 
(B) Confocal images of mammospheres with and without p120.  Mammo-
spheres were stained with Hoechst dye and fluorescently labeld phalloidin to 
mark actin.   
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 knockdown/addback experiments using wound-healing assays as a read out. Figure 12C 
shows selected images from time-lapse movies (Fig.12C).  As also observed in vivo, p120 
depletion did not alter cell proliferation (data not shown).  However, while TEB 
outgrowth was delayed in the p120 KO gland, wound closure in vitro by p120 KD 
MCF10A cells was not impaired, and individual p120 KD cells in fact migrated faster 
than their parental counterparts (Fig.12D).  Thus, the delay in TEB outgrowth is not 
likely to stem from a migration defect per se.  Instead, the data suggest that p120-
deficient cells simply fail to participate in the collective migration process due to loss of 
cell-cell adhesion (Fig. 12C).  
To determine whether p120’s role in collective migration is dependent on 
cadherin association, we tested a mutant form of p120 isoform 3 that is driven to the 
membrane by a CAAX box but cannot bind cadherins (3A Δarm1.CAAX) (Wildenberg et 
al. 2006, Fig.15).  In contrast to p120-3A, the mutant did not rescue collective migration, 
suggesting that p120’s role in this process is cadherin-dependent (Fig. 12C). Depletion of 
either E-cadherin or N-cadherin individually from MCF10A cells did not disrupt 
collective migration, suggesting that one can stand in for the other. p120 depletion, on the 
other hand, is effective because it reduces all classical cadherins (Fig.14).   
 Collectively, these observations predict that branching morphogenesis will be 
impaired or altogether blocked if p120 is unavailable.  Thus, we examined the effects of 
p120 depletion in vitro and in vivo on branching morphogenesis (Fig. 16). PMECs were 
formed into mammospheres and induced to branch using FGF2 (McCaffrey and Macara 
2009, Ewald et al., 2008).  In the absence of p120, branching was reduced, and often 
failed entirely (Fig.16A-C).  p120 depletion is illustrated in figure 17.  Note that when 
Figure 14. Depletion of either E- or N-cadherin 
does not disrupt collective migration
(A) Lysates from parental MCF10A cells and two representative monoclonal 
cells lines from p120, E-cadherin, or N-cadherin knockdown were analyzed by 
immunoblotting for E-cadherin, N-cadherin, and P-cadherin.  Tubulin levels 
were used as a loading control. Note that while p120 depletion reduces all 
classical cadherins present, depletion of individual cadherins does not reduce 
other cadherins.  (B) Colony formation is maintained in E- or N-cadherin 
depleted MCF10A cells.  (C) Representative images from time-lapse micros-
copy of wound healing assays of E-cadherin or N-cadherin depleted MCF10A 
cells. Scale bar = 50 μM.    
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Figure 15. Expression of mutant p120 3A without armadillo repeat 1 in 
p120 depleted cells does not stabilize endogenous cadherin
A mutant form of p120 that cannot bind cadherins but is driven to the mem-
brane because of CAAX sequences (3A.Δarm1.CAAX) was expressed in 
MCF10A p120i cells.  (A) Expression was confirmed by immunofluorescence 
with 8D11, an antibody that recognizes only mouse p120.  (B) Lysates from 
parental MCF10A, p120i, p120i expressing isoform 3A, and p120i expressing 
mutant 3A cells were analyzed by immunoblotting for p120 and E-cadherin.  
Tubulin levels were used as a loading control.  Note that E-cadherin is not 
stabilized by mutant p120 3A.  (C) Colony formation is not rescued by cad-
herin binding defective mutants.  All scale bars = 50 μM.
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Figure 16. p120 is necessary for in vitro mammary branching 
and in vivo gland reconstitution
(A-D) PMECs infected with either control GFP or p120i GFP virus were 
subjected to branching assays as described in the materials and methods.  
(A) Representative images of control and p120-depleted branched mammo-
spheres.  Yellow dotted lines depict absence of p120-depleted cells in TEB-
like structures.  (B) Quantification of percent branched mammospheres from 
5 independent experiments. Student’s t-test. (C) Representative quantifica-
tion of branches per mammosphere.  Median values are listed.  3 indepen-
dent experiments were performed.  Student’s t-test. (D) Representative 
graph of the percent of GFP-positive branches per mammosphere. 3 inde-
pendent experiments were performed.  Student’s t-test. (E) In vivo mammary 
reconstitution assays.  Representative fluorescent images of whole mounts 
are shown.  Data are mean percent outgrowth +/- s.e.m...  Paired t-test n=6. 
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Figure. 17. Depletion of p120 in 3D branching assays 
of primary mammary epithelial cells
Immunostaining for p120 and E-cadherin was performed on mammospheres 
induced to branch with FGF2.  (A) Confocal images of p120 and GFP in 
mammospheres expressing control and p120 depletion constructs.  (B) 
Confocal images of p120 and E-cadherin in mammospheres.
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 branching was observed, p120 was invariably retained (i.e. GFP negative)(Fig.16D).  
When transplanted into cleared fat pads, p120i PMECs were unable to reconstitute the 
gland (Fig.16E).  Control cell formed clearly identifiable ducts and TEBs, whereas p120-
depleted cells manifested as thin strands and small cell groups without discernable 
structure.   
 
Discussion 
 The effects of p120 knockout in different organ systems are highly variable. Here, 
we show that p120 plays an essential role in the morphogenesis of the mammary gland.  
Ductal architecture is rapidly compromised and p120-null cells disappear altogether 
within a few weeks.  In the TEB, p120 null cells are virtually unable to participate in the 
dynamic rearrangements required for invasion and morphogenesis. Functional analyses in 
vitro reveal severe defects in cell-cell adhesion and a striking failure of collective 
migration. Thus, it appears that mammary gland development depends on p120 because 
the TEB, the main functional unit of mammary development, is effectively disabled by 
p120 ablation.  
 In our current mouse model, the severity of the phenotype is largely masked by 
the mosaic nature of the p120 knockout.  The phenotype ultimately manifests as little 
more than a delay in ductal penetration, but in fact reflects massive sorting and 
elimination of p120 null cells such that very few remain 3 weeks after p120 ablation. 
From there on out, the “knockout” gland is essentially p120 positive and morphogenesis 
proceeds normally.  The strong selective pressure for cells that have retained p120 
suggests that if the knockout had been complete, the gland would not have formed at all. 
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Anecdotal evidence from previous studies of p120 ablation in the salivary gland using a 
different MMTV-Cre mouse suggests that this is, in fact, the case.  Indeed, although the 
vast majority of these animals died shortly after birth, females that survived into 
adulthood were completely devoid of mammary ductal trees (Davis and Reynolds, 2006).  
Our in vivo PMEC assays confirm these findings, as p120i cells are unable to form a 
mammary gland (Fig.16E). 
 Interestingly, in vitro p120 depletion in different epithelial cell types results in a 
wide spectrum of adhesion phenotypes. For example, mammary MCF10A cells separate 
completely from one another in 2D cultures, whereas similarly cultured MDCK cells 
lacking p120 form normal appearing colonies that are essentially indistinguishable from 
parental controls (Fig.12B, Dohn et al., 2009; Simpson et al., 2008).  More common is a 
spectrum of adhesive defects that fall between these extremes (Davis et al., 2003).  
Similarly, in vivo p120 KO phenotypes are surprisingly diverse. For example, although 
intercellular adhesive defects are not observed after p120 KO in the epidermis, a massive 
inflammatory response is induced by cell autonomous signaling defects associated with 
NFkB activity (Perez-Moreno et al., 2006).  In the prostatic epithelium, cadherin 
expression is nearly eliminated by p120 ablation and glandular morphology appears to be 
virtually unaffected (A.B. Reynolds, unpublished).  In salivary gland and intestinal 
epithelium, cadherin-depletion is more moderate following p120 KO (i.e. ~50% depletion 
relative to control epithelium), but nonetheless causes obvious adhesion defects with 
extensive cell shedding (Davis and Reynolds, 2006; Smalley-Freed et al., 2010).  Cell- 
and tissue-specific contexts are clearly critical and contribute along with other factors to 
the ultimate effect of p120 ablation. 
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 Our in vivo data reveal that the TEB is extraordinarily sensitive to p120 ablation.  
Interestingly, an unbiased in vitro RNAi screen for proteins affecting MCF10A cell 
motility identified both p120 and P-cadherin as central mediators of collective migration 
(Simpson et al., 2008). The result highlights the often overlooked fact that p120 stablizes 
all classical cadherins, and implies an activity for P-cadherin that might not be shared by 
E- and/or N-cadherin (at least in MCF10A cells).  Similarly, p120 is required for 
cadherin-dependent collective invasion in an A431 squamous carcinoma cell model 
(Macpherson et al., 2007). Eric Sahai’s group has recently proposed that collective 
migration is controlled in part by an E-cadherin/DDR1/Par3-Par6 complex that functions 
to limit actomyosin contractility as needed at adherens junctions through mechanisms 
involving p190ARhoGAP and RhoE (Hidalgo-Carcedo et al., 2011).  Although not 
directly included as part of the Sahai model, p120 is likely to play a role.  We have 
previously demonstrated that interactions between p120, RhoA and p190RhoGAP 
function to limit contractility at N-cadherin-based adherens junctions in NIH3T3 cells 
(Wildenberg et al., 2006).  Thus, one possibility is that p120 functions in the Sahai model 
as part of the machinery that enables collective migration by suppressing RhoA.  Indeed, 
p120-depleted MCF10A cells are highly contractile and demonstrate readouts indicative 
of high Rho activity (data not shown).  Alternatively, p120-ablation may simply override 
the normal mechanisms for modulating collective migration by depleting E-cadherin to 
levels that cannot sustain cell-cell adhesion.  These models are not necessarily mutually 
exclusive.  Exactly how E-cadherin levels are controlled by p120 is not well understood 
and could conceivably be related to novel concepts proposed by Sahai and colleagues.   
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 Although TEB defects associated with p120 ablation could in principle stem from 
events unrelated to loss of E-cadherin (e.g., dysregulation of Kaiso activity) (Daniel and 
Reynolds, 1999), the evidence overall points strongly to E-cadherin depletion as the 
dominant, if not the sole driver of the phenotype.  p120 is required for the stability of all 
classical cadherins, including the E- and P-cadherins found in luminal and basal cells, 
respectively.  Accordingly, E-cadherin neutralizing antibodies selectively disrupt the 
body cell layer, whereas those for P-cadherin disrupt only the cap cell layer (Daniel et al., 
1995).  TEB activity stalls in either case, indicating that both layers must be intact for the 
TEB to function normally.  Notably, the cell-cell adhesion defects associated with 
cadherin blocking are morphologically almost indistinguishable from those induced by 
p120 ablation, and both mechanisms clearly act through disabling cadherins. Thus, the 
effects of p120 ablation on cadherin loss are sufficiently severe in the TEB that secondary 
and/or less obvious consequences of p120 ablation, if present, go undetected.  For 
example, cell polarity proteins interact functionally with cadherin complexes (Qin et al., 
2005, Navarro et al., 2005, Zhan et al., 2008), but may be largely disabled in the context 
of severely compromised cell-cell adhesion.   
 Surprisingly, p120 family members were unable to compensate for loss of p120, 
despite evidence that they can effectively rescue cadherin stability and cell adhesion in 
vitro (Davis et al. 2003).  Figure 10 illustrates clearly the significant presence of all three 
family members in p120 KO tissue. It is unclear whether this failure to rescue p120-
ablation extends to other organs.  In most epithelial tissues, including the epidermis, GI 
tract and salivary glands, cadherin levels are reduced but not decimated to the extent 
observed in the mammary gland.  In fact, on average, p120 ablated tissues tend to retain 
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between 25 and 50% of cadherin levels found in control tissue (Davis and Reynolds, 
2006; Perez-Moreno et al., 2006; Smalley-Freed et al., 2010).  In vivo correlations where 
available appear to support the in vitro data in that p120 family members have been 
found in tissues where p120-ablation does not result in complete cadherin loss (Marciano 
et al., 2011; Perez-Moreno et al., 2006).  However, whether endogenous p120 family 
members do in fact compensate for p120 loss in vivo has yet to be directly demonstrated 
in any tissue (e.g., by in vivo double KO).  In the TEB, the near complete absence of both 
cadherins and junctional β-catenin following p120 ablation indicate that these potential 
compensatory mechanisms are either insufficient or inactive.  
 Although p120 knockdown in vitro induced severe distortions in MCF10A 
mammosphere morphology, the cells themselves were healthy and persisted indefinitely. 
In contrast, p120 ablated cells in the developing mammary gland were rapidly lost and 
rarely observed past week 6. Interestingly, detached cells were frequently TUNEL and 
cleaved caspase-3 positive.  Thus, while the exact mechanism of cell death is not clear, 
our detachment and apoptosis data imply a form of anoikis (Wang et al. 2003, Gilmore 
2005). 
 In contrast to several other tissues (Perez-Moreno et al., 2006; Smalley-Freed et 
al., 2010), we did not observe significant inflammation. It may be that recognition and 
removal of p120 null cells does not require de novo influx of immune cells.  Rather, in 
the greater scheme of active TEB invasion, efficient removal of p120 null cells by 
already present tissue-resident macrophages may be sufficiently routine to go largely 
unnoticed. Tissue-resident macrophages are known to actively participate in TEB-
proximal stromal remodeling and were in fact detected at normal levels (Gouon-Evans et 
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al., 2002; Ingman et al., 2006). Additionally, these cells may also be cleared by 
neighboring mammary epithelial cells via efferocytosis, a phagocytic process recently 
shown to be important during involution of the mammary gland (Monks et al., 2008; 
Sandahl et al. 2010). 
 In conclusion, we demonstrate for the first time that p120 is essential for 
mammary gland development. The explanation likely lies in the extraordinary sensitivity 
of the TEB to p120 loss and the dependence of TEB function on collective migration, a 
phenomenon based on dynamically regulated cell-cell adhesion.  Our work extends 
previous observations on the role of p120 in collective migration (Hidalgo-Carcedo et al., 
2011; Macpherson et al., 2007; Simpson et al., 2008) to a highly relevant in vivo setting 
and is in line with prior anecdotal evidence that mammary development essentially fails 
altogether in the absence of p120 (Davis and Reynolds, 2006).  Given the unique 
morphogenetic status of the TEB, it will be interesting in future work to extend these 
studies to p120 KO in breast cancer models as well as fully developed mammary 
epithelium. 
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CHAPTER IV 
 
P120 ABLATION POTENTIATES A MOUSE MODEL OF BREAST CANCER, BUT 
IS PARADOXICALLY REQUIRED FOR METASTASIS 
 
Introduction 
 p120 is critical for tissue integrity and cell-cell adhesion, disruption of which is 
associated with diseased states of inflammation and cancer.  p120 performs a variety of 
cancer-relevant tasks in the cell, including cadherin stabilization and modulation of 
RhoGTPase activity, yet the exact mechanisms of p120 function in the transformed 
epithelium remains unclear and is likely tissue and context specific.  As such, the role of 
p120 in tumorigenesis and progression is an active area of research.  
 Alterations in cadherins, the central components of adherens junctions, play a role 
in breast tumor initiation, progression, and metastasis (reviewed Wheelock et al., 2001).  
E-cadherin, the predominant cadherin expressed in mammary epithelial cells, is well 
established as a tumor and metastasis suppressor (Perl et al., 1998, Derksen et al., 2006, 
reviewed in Birchmeier and Behrens 1994, and in Jeanes et al., 2008).  Experimental 
ablation of E-cadherin leads to increased metastasis in a mouse model of lobular breast 
cancer and re-expression in E-cadherin-deficient cell lines frequently blocks metastases 
(Vleminckx et al., 1991, Mbalaviele et al., 1996, Derksen et al., 2006).  In contrast, 
mesenchymal cadherins, such as N-cadherin and cadherin-11, are not expressed in the 
normal mammary epithelium.  They are, however, upregulated in human breast tumors 
and are likely involved in progression to metastasis (Niemann et al., 1999, Hazan et al., 
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2000, Kim et al., 2000, Nagi et al., 2005, Yanagisawa and Anastasiadis, 200, Hulit et al., 
2007).  For example, forced expression of N-cadherin in either human breast cancer cells 
or a mouse model of breast cancer leads to increased invasion in vitro and metastasis in 
vivo (Hazan et al., 2000, Hulit et al., 2007).  This dichotomy between E-cadherin and 
mesenchymal cadherins is at the heart of epithelial plasticity, namely EMT and the 
reverse process, MET (reviewed in Kalluri and Weinberg 2009).  Recent work has linked 
EMT to breast cancer stemness and has started to elucidate the specific pathways that 
control the ability of these cells to colonize distant tissues (Mani et al., 2008, Malanchi et 
al., 2012). Cadherins are also essential for collective invasion, adding yet another 
dimension to their role(s) in the metastatic cascade (Reviewed in Friedl and Wolf, 2003).  
Thus, cadherins, their control of cell-cell adhesion and migration processes, and their 
regulation of cellular signaling are critical mediators of breast cancer metastasis. 
  Changes to p120 behavior in carcinomas, including breast cancer, are well 
documented in the literature (reviewed in Thoreson and Reynolds 2002). In lobular breast 
carcinomas, p120 is characteristically mislocalized to the cytoplasm in response to E-
cadherin loss (Sarrio et al., 2004, others), and instances of p120 upregulation have been 
documented in Her2 positive and inflammatory breast cancer (Landis et al., 2005, Silvera 
et al., 2009, Johnson et al., 2010).  The most frequent change, however is 
downregulation, observed in over 50% of human breast ductal carcinomas (Sarrio et al., 
2004), and regions of complete p120 loss were reported in approximately 10% of ductal 
carcinomas (Dillon et al., 1998, Nakopoulou et al., 2002).  This downregulation is 
recapitulated during the progression from adenoma to carcinoma in the MMTV-PyMT 
mouse model of breast cancer (Kouros-Mehr et al., 2008). In humans, downregulation of 
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p120 is correlated with poor outcome in patients with invasive breast cancer (Talvinen et 
al., 2010).  However, the importance of p120 downregulation in the overall scheme of 
breast cancer progression  remains unclear.  
 Evidence exists for p120 acting as both a metastasis promoter and suppressor in 
the context of breast cancer. Since p120 stabilizes a known metastasis suppressor, E-
cadherin, p120 downreguation may promote invasion and metastasis by destabilizing E-
cadherin  (Behrens et al., 1989, Davis et al., 2003).  However, Anastasiadis and others 
have proposed that the stability of mesenchymal cadherins (e.g. N-cadherin and cadherin-
11) is required for acquisition of true invasiveness (Yanagisawa and Anastasiadis 2006, 
Yanagisawa et al., 2008).  According to this model, p120 ablation also reduces 
mesenchymal cadherin levels, which in turn are essential for invasion and metastasis.   
Interestingly, inflammatory breast cancer (IBC) is unique in that its highly 
metastatic behavior depends on upregulation of p120. In IBC, p120 levels are aberrantly 
elevated by an IRES-dependent translational mechanism induced by inflammatory stress 
(Silvera et al., 2009). E-cadherin is upregulated in tandem and resulting in formation of 
tumor emboli and a highly aggressive form of breast cancer that spreads by a process 
known as passive metastasis. Tumor emboli colonize other tissues via diffusion through 
lymphovascular spaces.  In vitro and in vivo work demonstrates that the ability of p120 to 
stabilize E-cadherin is essential for both metastatic emboli formation and tumor cell 
survival (Silvera et al., 2009).  The IBC phenomenon highlights the fact that disregulation 
of p120 levels in either direction leads to adverse effects relevant to cancer.   
 Cadherin-independent functions of p120 may also contribute to metastatic 
outcome.  For example, E-cadherin loss in lobular breast cancer leads to cytoplasmic 
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localization of p120, which is critical for growth and metastasis by mechanisms involving 
control of small GTPases (Schackmann et al., 2011).  In MDA-MD-231 cells, abrogation 
of invasion following p120 loss is rescued by expression of constitutively-active Rho, 
suggesting that p120’s inhibition of Rho promotes invasiveness (Yanagisawa and 
Anastasiadis, 2006).  This finding is possibly clinically relevant as overexpression and 
increased activity of Rho proteins is associated with malignancy in breast (Fritz et al., 
1999, Fritz et al., 2002).  Thus, p120 can inhibit Rho by several mechanisms and this 
activity appears to play a role in breast cancer metastasis (Anastasiadis et al., 2000, 
Wildenberg et al., 2006, Smith et al., 2012).      
 Non-cell autonomous consequences of p120 ablation (e.g. inflammation) have  
also been implicated in metastasis.  For example, ablation of p120 in the epidermis 
induces activation of NFkB, secretion of cytokines, and increased infiltration of immune 
cells (Perez-Moreno et al., 2006, Smalley-Freed et al., 2010, Stairs et al., 2011). These 
observations illustrate multiple context and tissue-specific roles for p120.  Clearly, the 
consequences of p120 ablation in the context of breast cancer are not entirely predictably 
and will have to be determined empirically.  
 Here, we addressed this question directly through mammary-specific p120 
knockout in a mouse model of metastatic breast cancer, MMTV-PyMT (Guy et al., 1992, 
other citations).  We find that p120 ablation did not alter tumor growth or latency, but 
markedly affected tumor morphology. Control tumors were consistently a mix of a 
compact/solid morphology and pseudopapillary, however, regions of p120 ablation were 
uniformly pseudopapillary in nature.   Furthermore, these areas exhibited macrophage 
and myofibroblast infiltration, collagen deposition, and reduction of E-cadherin and 
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junctional β-catenin. p120 ablation directly induced macrophage recruitment and 
promoted the M2 phenotype, a pro-tumor/metastasis state, likely through a mechanism 
involving Ccl5 secretion.  Although PyMT p120 KO mice demonstrated a significant 
increase in number and size of pulmonary metastases, p120 null cells were rarely 
observed in pulmonary metastases, suggesting that p120 null cells in the primary tumor 
were potentiating metastases in an indirect manner.  Indeed, we find that p120 is in fact 
required for a late stage event in the metastatic cascade, likely colonization.  Overall, our 
data suggest that p120 ablation facilitates metastasis by non-cell autonomous 
mechanisms, but paradoxically completely blocks cell-autonomous metastasis. 
 
Results 
Loss of p120 does not alter latency or tumor growth but affects tumor histology 
 To directly test the function of p120 during mammary tumorigenesis and 
progression to metastasis, we analyzed the consequences of p120 ablation on the MMTV-
PyMT transgenic mouse line, a well-characterized model of breast cancer known to 
exhibit consistent pulmonary metastases (Guy et al., 1992, reviewed in Lin et al., 2003).  
To this end, we crossed our mammary-specific p120 knockout mice to the MMTV-PyMT 
line  (p120f/f; MMTV-Cre; MMTV-PyMT hereafter p120 KO PyMT) (Davis et al., 2006).  
Control mice were defined as floxed p120 mice expressing the Middle T antigen in the 
absence of Cre recombinase (hereafter PyMT Control).  Ablation of p120 in PyMT p120 
KO mice was confirmed by immunofluorescence and immunoblot analysis of primary 
tumors (Fig.18A-B).  Expression of MMTV-driven cre recombinase yielded an average 
of 38.3% p120 negative cells per mouse (Range: 22.6-58.3%) (Fig.18C).   All tumors 
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Figure 18: p120 ablation in MMTV-PyMT does not affect tumor latency and volume
p120 null cells in knockout but not control mice were identified by both immunoblot (A) 
and immunofluorescence (B).  (C) The amount of p120 knockout per mouse was 
estimated by immunofluorescent staining of a random sampling of primary tumors from a 
given mouse. (D) Control and p120 ablated mice were monitored for tumors by palpa-
tion. (E) The volume of all ten mammary tumors per mouse were approximated by 
calipering (h*l*w=approx. volume) 54 days post palpation. No significant difference was 
observed using a logrank test. (F) To assess proliferation, PyMT tumors were stained for 
phosphorylated histone H3 by immunofluorescence. (G) To assess apoptosis, TUNEL 
was performed on PyMT tumors.  The percent of positive nuclei was assessed in 3 
different pseudopapillary regions per n=6 tumor of each genotype. No significant differ-
ence in rates of proliferation or apoptosis was observed.
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 exhibited some degree of knockout at both early and late stages suggesting that the 
Middle T antigen is sufficient to rescue the survival of p120 null mammary epithelial 
cells, which typically do not persist in the context of the developing gland (See Chapter 
3).           
 Primary tumor morphology, but not overall growth rate, was altered by p120 
ablation.  No differences were observed in tumor latency or final total tumor volume 
(Fig.18D-E).  Furthermore, while there was a trend toward both a decrease in 
proliferation and apoptosis in regions of p120 negativity, these data were not statistically 
significant (Fig.18F-G).  Interestingly, while there were no gross changes to tumor onset 
or volume, the morphological characteristics of the p120 null regions were dramatically 
altered in comparison to controls.  In hyperplastic lesions , the differences manifested as 
cell rounding and sloughing into the lumen (Fig.19A).  In later stages (54 days post 
palpation), p120 null regions were exclusively pseudopapillary, despite the equal 
distribution of compact and pseudopapillary lesions in PyMT control tumors (Fig.19B).   
 Given the known role of p120 in adherens junction stability and tissue 
architecture, we analyzed a number of junctional components by immunostaining.  Figure 
20 depicts a striking reduction in adherens junction components, E-cadherin and β-
catenin, in regions of p120 ablation (Fig.20A-B).  Given the ability of p120 family 
members, ARVCF, p0071, and δ-catenin, to rescue cadherin stability in the absence of 
p120 in vitro (Davis et al. 2003), we hypothesized that family members were completely 
absent in PyMT tumors (Fig.20C-E).  However, immunofluorescence demonstrated that 
all three family members were indeed expressed.  δ-catenin immunostaining appeared to 
be reduced in regions of p120 ablation, however separate analyses using other available 
Figure 19: p120 ablation results in cell rounding in hyperplastic ducts and a 
pseudopapillary phenotype
(A) Hyperplastic ducts from p120 KO PyMT tumors were imaged after hematoxylin and 
eosin staining or IHC for p120. (B) PyMT tumors were imaged after hematoxylin and 
eosin staining or IHC for p120.  While control mice exhibited both solid and 
pseudopapillary regions, p120 loss was confined to areas of pseudopapillary or papillary 
phenotypes
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Figure 20. Adherens junctions are disrupted by p120 ablation and family 
members do not compensate 
To assess adherens junctions, PyMT p120 knockout sections were stained for 
E-cadherin and β-catenin (A-B).  Representative images of regions of p120 
ablation depict loss of junctional E-cadherin and β-catenin.  To assess the pres-
ence and localization of p120 family members p0071, ARVCF, and δ-catenin, 
immunofluorscence using antibodies against these proteins was performed 
(C-E).  Representative images of regions of p120 ablation depict no changes to 
p0071 or ARVCF. Scale bars = 50 uM
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 antibodies did not confirm this downregulation (Fig.20E, data not shown).  Overall, 
these data suggest that in the context of PyMT-induced tumorigenesis p120 acts to 
stabilize cadherin-based structures using a mechanism unable to be performed by other 
family members.   
 
p120 ablation induces alterations to the tumor microenvironment  
 Besides changes to the epithelium itself, p120 ablation induced dramatic changes 
to the tumor microenvironment.  To thoroughly analyze the stromal changes first 
observed via H&E analysis, we utilized flow cytometry and immunohistochemistry to 
globally and regionally assess different populations of immune cells.  Flow cytometry 
analysis of whole tumor or spleen yielded no statistically significant change in numbers 
of myeloid derived suppressor, T-, B-, or dendritic cells  (Fig.21). However, regions of 
p120 ablation exhibited increased myofibroblasts and macrophages as monitored by 
SMA and F4/80 immunostaining (Fig.22A-B). SMA marks many cell types, thus we also 
analyzed these SMA positive cells for expression of keratin 5.  Given that keratin 5 rarely 
stained positive in SMA positive cells (data not shown), we reasoned that these SMA+ 
cells were likely myofibroblasts, rather than myoepithelial cells.  To assess the 
endothelium, we utilized antibodies against Meca32 (pan-endothelial), VonWillebrand 
Factor (macrovasculature) and CD31 (microvasculature).  None showed a significant 
change in regions of p120 loss (Fig.22C-D, data not shown). T-cell numbers were also 
unchanged as assessed by IHC for CD3 (Fig.22E). Regions of p120 ablation also 
demonstrated a striking upregulation of collagen as monitored by trichrome blue staining 
A     Tumor
B     Spleen
Figure 21. Flow cytometric analysis of PyMT tumors and spleens
Tumor (A) and spleens (B) from PyMT Control (white) and p120 KO 
(black) mice 30 days post palpation (n=5 per genotype) were analyzed by 
flow cytometry.  All analyses are shown as % positive of DAPI-CD45+ and 
cell type specific markers listed in Table 3.  Mann-Whitney tests compar-
ing control to p120 KO for each cell type yielded no significant differences. 
Graphs depict mean +/- SEM.  
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 (Fig.22F).  Thus, p120 ablation induced specific changes to the mircoenvironment and 
these alterations occurred in regions of p120 loss rather than globally/systemically.  
 Macrophages are known to play a role in tumor progression (reviewed in 
Condeelis and Pollard, 2006, in Joyce and Pollard, 2009), thus, we next analyzed 
macrophage infiltration and phenotype.  To test the effects of p120 ablation on total 
macrophage recruitment, whole tumors were analyzed by flow cytometry (CD45+, 
CD11b+, F4/80+).  By this method, total macrophage number was unaltered in PyMT 
p120 KO mice (Fig.23A).    Given that macrophage phenotypes of M1 and M2 are 
associated with anti- and pro-tumor progression, respectively (reviewed in DeNardo and 
Coussens, 2007), we assessed their phenotype by two different methods.  Using flow 
cytometry of known cell surface markers, there was no change in the number of M1 
macrophages, however PyMT p120 KO tumors contained a significant increase in the 
number of M2 macrophages (Fig.23B).  To assess transcript levels associated with 
macrophage phenotype, RNA from triple positive, CD45+, CD11b+, and F4/80+, tumor 
macrophages was collected and subjected to real-time PCR analyses.  These data 
demonstrated a statistically significant increase in MMP2 and MMP9, two well-defined 
markers of M2 phenotype, with a decrease to M1 markers, TNFα, and IL12b (Fig.23B).  
Thus, by two independent methods, p120 ablation increased the prevalence of an M2 
phenotype in tumor-associated macrophages.   
 To test the possibility that p120 null cells directly recruit macrophages, we 
analyzed the ability of isolated macrophages to invade through Matrigel-coated filters in 
response to secreted media from PyMT-derived cell lines manipulated ex vivo to express 
control or Cre vectors.  3- to 10-fold more peritoneal macrophages invaded through 
Figure 23. p120 ablation induces M2 macrophage phenotype 
and macrophage invasion 
 (A) Representative FACS plots of macrophage numbers in tumor tissue. Plots 
are gated as CD45+DAPI-, (B) Flow cytometry analysis of 
CD45+CD11b+F4/80+ cells in tumor tissue. (C) Quantitative RT-PCR on 
CD45+CD11b+F4/80+ cells from PyMT Control and PyMT p120 KO tumor 
tissues sorted by FACSAria and converted to cDNA. Data are shown as fold 
over control. (D) Monoclonal or polyclonal matched PyMT-derived cell lines 
were grown in 3D cultures.  After establishment of colonies, serum free media 
was added and collected after 24 hours.  Peritoneal macrophages were derived 
and plated onto Matrigel-coated transwells.  Macrophages were allowed to 
invade for 48 hours toward control or p120 KO cell secreted media.  This graph 
is representative of two replicates.  10 fields per transwell were assessed for 
number of cells per field. p value for Student’s t-test.
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 Matrigel in response to secreted media from PyMT p120 KO cells which suggested that 
in vivo, p120 null cells were more proficient at recruiting macrophages than their 
wildtype counterparts (Fig.23C).  Cytokine arrays performed on secreted factors from 
PyMT control or p120 KO cells grown in 3D provided a list of candidates for this direct 
recruitment (Fig.27C).  One cytokine identified as upregulated in PyMT KO cells, 
Ccl5/Rantes, is known to increase monocyte recruitment and facilitate M2 skewing 
(Azenshtein et al. 2002, Mantovani et al. 2007, Robinson et al. 2003).  Thus, these arrays 
provided likely candidates for the direct effects of p120 ablation on macrophage 
recruitment and M2 phenotype.  In summary, p120 ablation and subsequent changes in 
cytokine production appeared to directly increase infiltration of macrophages, which are 
enriched for M2 phenotype, a pro-progression/pro-metastasis state.     
 
p120 ablation potentiates PyMT-induced metastasis, yet its expression is required for 
pulmonary colonization 
 Given the striking changes to the epithelium and microenvironment induced by 
p120 ablation, we hypothesized that p120 ablation alters metastasis.  To directly test the 
effects of p120 loss on breast cancer metastasis, pulmonary tissue from mice 54 days 
after initial tumor palpation was analyzed for tumor burden.  A statistically significant 
increase in number of pulmonary metastases as measured by lung whole mount was 
observed in PyMT p120 KO mice (median of 3 in controls compared to 12.5 in KO) 
(Fig.24A).  There was also a striking increase in lung metastasis size in the PyMT p120 
KO mice as quantified in H&E stained sections of lung (Fig.24B-C).  If p120 ablation 
potentiates metastases in a cell autonomous manner, it follows that p120 null cells would 
Figure 24. p120 ablation increases number and 
size of pulmonary metastases 
(A) Hematoxylin whole mount analysis and counts of surface lung metastases 
were performed on mice 54 days post tumor palpation.  Metastasis was com-
pared using a Mann-Whitney test *p<0.05 (B) Metastases size was measured 
on lung sections stained with H&E. (C) Representative sections are shown. 
Lungs from PyMT p120 knock out mice were stained for p120 and keratin 8 by 
immunofluorescence.  After identification by keratin 8, lung metastases were 
analyzed for p120 status.  (D) Representative examples of pulmonary metasta-
ses stained for p120 and keratin 8.(E) Collective data (F) p120 status of lung 
metastases from individual mice. Almost all metastases from KO mice retained 
p120.  
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 dominate the lung metastases of PyMT p120 KO mice.  In fact, we observed the 
opposite.  PyMT control metastases always retained p120, however PyMT p120 KO mice 
rarely exhibited wholly p120 null metastases (Fig24D-F).  By co-immunostaining for 
keratin 8 and p120, only 1 in 6 PyMT p120 KO mice demonstrated any completely null 
pulmonary tumors, and 2 of 6 demonstrated only completely p120 positive tumors.  
These data suggested that the increase in metastases observed in PyMT p120 KO mice 
occurred via a non-cell autonomous mechanism, and p120 null cells are themselves 
metastasis deficient.   
 To directly test the metastatic capacity of PyMT p120 null cells, we generated 
matched panels of PyMT-derived cell lines.  While variable, a high percentage of cells 
with total p120 ablation was achieved using retrovirus expressed Cre recombinase 
(example of 1 such polyclonal line in Fig.25A).  This matched pair demonstrated 
indistinguishable tumor growth kinetics when injected into the orthotopic site (Fig.25B).  
However, the absence of p120 prevented pulmonary metastases (0% of mice injected 
with KO cells compared to 77.8% of those with control cells), despite both lines being 
equally locally invasive (Fig.24C-D).  To assess the motility and invasion in vitro, wound 
healing and Matrigel invasion assays were performed with 3 different matched sets of 
PyMT-derived cell lines.  While control cells closed the wound utilizing a mixture of 
collective and single cell migration, p120 KO cells migrated solely as single cells 
(Fig.25E).  No differences in migratory rate were observed.  However, invasion was 
increased in the absence of p120 thus providing further evidence that p120 is not required 
for early stages of the metastatic cascade (Fig.25F).  In fact, its absence apparently 
promoted the first steps of metastasis.   
Figure 25. p120 loss induces single cell migration and
 increased invasion, but inhibits metastasis
(A) PyMT-derived cells were infected with empty or Cre expressing retrovirus 
to generate control or KO cells.  (A) Co-immunofluorescence for p120, 
E-cadherin, and Keratin 8 confirms a predominantly p120 negative, keratin 
positive cell line. KO cells are fibroblastic on plastic compared to cobblestone, 
epithelial control cells. (B) Tumor growth of control and p120 KO cells trans-
planted into the orthotopic site of nude mice was monitored by calipering (C-D) 
Pulmonary metastases were assessed by H&E of lung sections. Both control 
and KO cells are locally invasive when transplanted into the orthotopic site of 
nude mice. However, Control cells, but not KO cells metastasize to the lungs 
when transplanted into mammary glands of nude mice.  Representative H&E 
stained sections of pulmonary tissue are shown above.  The arrow denotes a 
metastasis. (E) Matched monoclonal and polyclonal PyMT-derived cell lines 
were plated to confluence and subjected to wound healing assays.  Time-lapse 
microscopy demonstrates that while control cells migrated with a mixture of 
collective and single cell motility, p120 KO cells moved only as single cells.  
Representative images at 0 and 12 hours are shown. (F) Invasion assays were 
performed using these cells and Matrigel coated transwells.  Assays were 
performed in duplicate and a representative graph is shown.  10 random fields 
of view per transwell were assessed after 36 hours.  Student’s t-test *p<0.001  
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 Metastatic deficiency in the absence of p120 could occur at a variety of steps in 
the metastatic cascade.  To identify the exact stage of metastatic deficiency, we 
performed a battery of experiments to dissect other aspects of the metastatic cascade.  
First, equal colonies were formed from blood of late stage PyMT control or p120 KO 
mice which suggested that p120 ablation did not significantly alter circulating tumor cell 
number (Fig.26C).  Furthermore, when assayed for survival in suspension, one 
requirement of circulating tumor cells, control and p120 KO cells exhibited similar low 
levels of death suggesting that p120 ablation did not prevent survival in the blood stream 
(data not shown).  To test the ability of p120 null cells to grow in the absence of 
extracellular matrix, PyMT cells were grown in 3 dimensional agarose.  Here, p120 was 
required for PyMT-mediated anchorage-independent growth.  As a positive control, cells 
were grown in Matrigel and, consistent with our in vivo data, exhibited structural but not 
growth differences in the presence of ECM (Fig.26B).  These data suggested that a 
certain threshold of ECM is required for p120 null cells to grow.  Furthermore, the 
inhibition of anchorage-independent growth, a stringent assay of tumorigenicity, in p120 
ablated cells suggested that p120 was required for lung colonization, a form of 
tumorigenesis.  To directly test this hypothesis, tail vein injections were performed with 
two different control and p120 KO clones.  Control PyMT-derived cells reproducibly 
generated pulmonary tumors indicating that they recapitulated the colonization of the 
original mouse model (Fig.26D-F).  However, p120 KO clones were completely deficient 
in colonization (Fig.26D-F).  Coupled with the observation of a preference for p120 
positive cells in the genetic model pulmonary tissue, these assays suggested that p120 
was required for the late stages of the metastatic cascade, specifically colonization. 
Figure. 26 p120 is required for anchorage independent growth 
and pulmonary colonization
(A) PyMT-derived cell lines were grown in agar for 3.5 weeks.  Representative 
images at 2.5x and 20x magnification are shown. (B) Cells were grown in 
Matrigel as described in the materials and methods.  Representative images 
are show.  (C) Whole blood was plated on matrigel and colony formation from 
circulating tumor cells was assessed. Graph depicts number of colonies per 
2.5x field. Mann-Whitney test n.s. (D-F) PyMT-derived cells were injected into 
the tail veins of female mice and lung tumor burden was quantified after 4 
weeks.  (D) Quantification of tumor burden. Mann-Whitney *p<0.01. Represen-
tative lung whole mount images (E) and H&E stained lung sections (F).  
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 Finally, we sought to indentify mechanisms for the above-described alterations in 
microenvironment and metastasis.  To identify the changes induced by p120 ablation, 
mircoarray and cytokine array analyses were performed on RNA and secreted factors 
from PyMT-derived cells grown in 3 dimensions, respectively (Fig.27A).  A list of 
transcripts that were similarly up or downregulated in 3 different PyMT p120 KO cell 
lines (2 monoclonal and 1 polyclonal) compared to their respective control cell line is 
supplied in figure 27B.  Independent Kegg Pathway analysis of either the polyclonal or 
monoclonal set of matched cell lines identified chemokine signaling pathways and 
cytokine-cytokine receptor interactions as networks whose components are altered in the 
absence of p120 (Fig.27D-E) was conducted.  Furthermore, pathways involved in cell 
motility and growth, such as axon guidance and ErbB signaling, were identified as being 
enriched for transcripts.  Overall, these data suggested possible mechanisms of p120 
ablation-induced phenotypes.  Whether these changes are specific to p120 ablation and 
recapitulate the changes in vivo remains to be seen.  
Discussion 
 Here, for the first time, we directly tested whether p120 acts as a metastasis-
promoting or -suppressing agent in vivo by analyzing p120 ablation in the context of 
PyMT-driven tumorigenesis.  While tumor growth and latency were unchanged (Fig.18), 
p120 loss significantly increased pulmonary metastases suggesting p120 acts as a 
metastasis-suppressing agent (Fig.24).  However, PyMT-derived p120 null cells were not 
intrinsically metastatic but rather facilitated the metastasis of cells retaining p120 by a 
non-cell autonomous mechanism (Fig.25&26).  The increased metastasis was likely the 
indirect result of changes to the microenvironment, namely increased collagen,  
Figure 27. List of transcripts and cytokines altered by p120 ablation
(A) Schematic for cytokine and microarray studies with matched PyMT-derived 
cell lines (B) List of microarray targets consistently altered at least 2-fold in 3 
biological replicates. (C) Changes to cytokine secretion in p120-ablated cells 
compared to control. (D) Kegg pathway analysis of transcripts altered in two 
monoclonal KO clones compared to their matched control.  (E) Kegg pathway 
analysis of transcripts altered in a polyclonal KO line compared to its matched 
control.
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macrophages, and myofibroblasts (Fig.22&23).  Surprisingly, p120 was required for 
metastasis, specifically colonization, indicating that p120 is actually a metastasis-
promoting agent, cell autonomously.  
 
p120 loss is insufficient to disrupt PyMT-driven tumorigenesis 
 The seemingly contradictory role of p120 in tumorigenesis likely reflects cell-
autonomous and non-cell autonomous functions of p120.  p120 ablation is sufficient to 
produce neoplasia in a variety of organ systems and, in some cases, frank carcinoma 
suggesting that p120 is a bone-fide tumor suppressor (Davis and Reynolds, 2006, Perez-
Moreno et al., 2006, Perez-Moreno et al., 2008, Smalley-Freed et al., 2011, Stairs et al., 
2011).  The concomitant inflammation induced by p120 loss in these models likely 
reflects one underlying mechanism of tumor formation (Perez-Moreno et al., 2006, Perez-
Moreno et al., 2008, Smalley-Freed et al., 2011, Stairs et al., 2011).  Indeed, inhibition of 
inflammation by a variety of methods blocks hyperplasia or transition to invasiveness, 
depending on the model (Perez-Moreno et al., 2008, Stairs et al., 2011).  On the other 
hand, p120 is required for tumorigenesis in other contexts (Soto et al., 2008, Dohn et al., 
2009, Silvera et al., 2009, Johnson et al., 2010, Schackmann et al., 2011).  p120 depletion 
in models of lobular, inflammatory, and Her2-driven breast cancer reduces tumor growth 
(Silvera et al., 2009, Johnson et al., 2010, Schackmann et al., 2011).  Furthermore, work 
from our laboratory and others indicates that p120 is required for anchorage-independent 
growth, an in vitro surrogate for tumorigenesis, in the context of transformation by 
specific oncogenes (e.g. Src and Rac)(Soto et al., 2008, Dohn et al., 2009).  
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 Despite these previously published works suggesting a role for p120 in 
tumorigenesis, we observed no alterations to overall tumorigenesis or growth in the 
absence of p120.  Our data suggest that expression of the PyMT oncogene, which 
activates a multitude of pathways (Dilworth, 2002, Lin et al., 2003), sufficiently 
overcomes any growth disadvantages that may be posed by p120 loss.  However, there 
was a noticeable absence of morphologically solid/compact tumors without p120.  
Whether these different lesions (i.e. solid and pseudopapillary) arise from the same cell-
of-origin or if their progression is similar has yet to be elucidated.  These data may reflect 
a requirement for p120 in the formation of a specific type of lesion (i.e. morphologically 
solid/compact carcinoma).  On the other hand, p120 ablation may simply lead to the type 
of tissue organization reflected in pseudopapillary lesions.  Depletion of E-cadherin or 
Scribble, a polarity protein intimately linked to cadherin complexes, also leads to 
winding, linearized lesions resembling the pseudopapillary regions of PyMT tumors (Qin 
et al., 2005, Derksen et al. 2006, Zhan et al., 2008).  However, no correlation between E-
cadherin status and compact versus scattered invasive ductal breast carcinoma was 
observed in a small set of patient samples suggesting that this finding might be context 
dependent (Hashizume et al., 1996).  Overall, while p120 ablation did not alter PyMT-
driven tumor growth, use of other models will be necessary to understand the full breadth 
of p120’s roles in diverse forms and pathways to breast cancer. 
 
p120 ablation facilitates metastasis by potentiating a pro-metastatic microenvironment 
 Despite the cell-autonomous requirement of p120 for cells to colonize, its ablation 
potentiates metastasis by fueling a pro-metastatic microenvironment.  In a variety of 
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tissues, inflammation and immune cell infiltration are the consequence of p120 ablation 
(Perez-Moreno et al., 2006, Perez-Moreno et al., 2008, Smalley-Freed et al., 2010, 
Smalley-Freed et al., 2011, Stairs et al., 2011).  Consistently, in our system, increased 
collagen, fibroblasts, and macrophages were observed in regions of p120 ablation 
(Fig.22), changes generally associated with metastatic progression (Reviewed in Joyce 
and Pollard 2009).  For example, p120 ablation in the esophagus and subsequent 
inflammatory response are sufficient to induce invasive tumors (Stairs et al., 2011).  
Dexamethasone treatment, an anti-inflammatory and immunosuppressant compound, is 
able to maintain the lesions as hyperplasias indicating that the immune cells and 
inflammation directly contribute to progression to invasiveness (Stairs et al., 2011).  
Thus, it is highly likely that p120-ablation induced changes to the microenvironment in 
the PyMT model are directly contributing to increased metastasis. 
 Regions of p120 ablation are associated with carcinoma associated fibroblasts 
(CAFs) and increased collagen, which are associated with reactive stroma and facilitate 
metastasis (reviewed in Ronnov-Jessen et al., 1996, in Bhowmick et al., 2004, in Kalluri 
and Zeisberg, 2006).  CAFs promote metastasis through numerous direct and indirect 
mechanisms (Dimanche-Boitrel et al., 1994, Lochter et al., 1997, Orimo et al., 2005, 
Grum-Schewensen et al., 2005, 2010).  For example, ablation of S100A4, which is 
produced by fibroblasts, reduces the number of pulmonary metastases of PyMT mice, 
indicating that factors produced by fibroblasts are able to promote metastasis  (Grum-
Schewensen et al., 2005, 2010).  CAFs also secrete cxcl12/SDF-1, which stimulates 
angiogenesis and promotes carcinoma cell proliferation, thus contributing to progression 
(Orimo et al., 2005).  CAFs are known to be active fibroblasts, which by definition 
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produce increased amounts of ECM components, including collagen (Tomesek et al., 
2002).  A direct link between collagen fibers and in vivo carcinoma cell invasion has been 
identified using elegant intravital imaging studies (Wyckoff et al., 2007).  Furthermore, 
increased tissue stiffness, one consequence of increased collagen and fibrotic stroma, 
promotes progression to malignancy (Paszek et al., 2005).  Thus, the increase in collagen 
and myofibroblasts (i.e. CAFs) caused by p120 ablation likely contribute both directly 
and indirectly to metastasis.    
 Tumor-associated macrophages (TAMs), also increased by p120 ablation, are 
known to mediate tumor progression by affecting: tumor cell invasion; inflammation; 
matrix remodeling; intravasation; seeding at distant sites; and angiogenesis (reviewed in 
Pollard, 2004, Condeelis and Pollard, 2007 and in Joyce and Pollard, 2009).  In human 
breast cancer, TAMs are correlated with poor prognosis (Lin et al., 2002, Bingle et al. 
2002).  Indeed, elimination of macrophages from the PyMT model abrogates metastasis 
suggesting that these macrophages are directly involved in disease progression (Lin et al., 
2001).  Our data indicate that p120 ablation leads not only to the direct recruitment of 
macrophages, but also their switching to an M2 phenotype (Fig.23D). This provides an 
likely explanation for the increased metastases in KO mice, as macrophages skewed 
toward the M2 side of the M1/M2 spectrum are widely accepted to potentiate tumor 
progression and facilitate metastasis (DeNardo et al., 2009, Reviewed in Mantovani et al., 
2007, in DeNardo and Coussens, 2007, in Sica et al., 2008).    
  p120 ablation stimulates these changes to macrophages, and ultimately 
metastases, by a mechanism that likely involves NFkB activation, ccl5 secretion, and 
MMP9 production.  Increased in vitro invasion by macrophages suggests that ablation of 
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p120 results in secretion of specific factors that facilitate this process.  While several 
cytokines are altered in vitro by p120 ablation (Fig.27), ccl5, one such upregulated 
cytokine, is known to facilitate macrophage recruitment providing a probable candidate 
for induction of our observed phenotype (Azenshtein et al. 2002, Mantovani et al. 2007, 
Robinson et al. 2003).  Furthermore, NFkB, a transcriptional activator of ccl5, is itself 
activated downstream of p120 loss in vivo (Wickremasinghe et al., 2004, Perez-Moreno 
et al., 2006, Stairs et al., 2011), thus suggesting a mechanism of upregulation of ccl5 in 
our system.  In addition to recruitment, promotion of M2 macrophage phenotype may 
also be the result of ccl5 secretion.  Ccl5 treatment of monocyte cell lines upregulates the 
M2 marker, MMP9 (Robinson et al., 2002) suggesting that macrophage phenotype 
switching is a direct result of factors secreted by p120 null cells.  While we have not 
directly tested the functions of ccl5 and MMP9 in our p120 knockout mice, previously 
published work strongly supports their contribution to increased metastases.  For 
example, MMP9 contributes to carcinoma EMT, invasion, and pulmonary metastasis  
(Hiratsuka et al., 2002, Rizki et al., 2008, Wang et al., 2011- oncogene), and increased 
MMP9 secretion from either macrophages or endothelial cells may prime the pre-
metastatic niche for tumor cell colonization (Hiratsuka et al., 2002).  Ccl5 is also able to 
directly stimulate invasion and metastasis of breast cancer cells (Karnoub et al., 2007).  
In patients, high CCL5 is part of a signature associated with poor-outcome in IBC 
patients and is associated with progressive malignancy in breast and cervical cancer 
(Niwa et al., 2001, Bieche et al., 2004).  Treatment with MetCCL5, an antagonist of 
CCR1 and CCR5, reduces tumor growth and immune cell infiltration (Robinson et al. 
2003).  Collectively, our data support a model wherein p120 ablation leads to 
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macrophage recruitment and M2 phenotype, including upregulation of MMP9, by 
intracellular activation of NFkB and secretion of ccl5 by KO cells (Figure 28). These 
changes to the macrophage population coupled with increased CAFs and collagen 
ultimately exacerbate metastasis.  
 
p120 is required for pulmonary colonization 
 The metastatic cascade describes the steps cancer cells take to achieve metastasis 
at secondary sites, namely: local invasion; intravasation; survival in the lymphatic or 
blood stream; extravasation; and growth at the secondary site/colonization (Reviewed in 
Valastyan and Weinberg 2001).  Overall, our data suggest that p120 is necessary for 
metastasis (Figs.25&26).  In some contexts, p120 depletion completely blocks motility 
and invasion (Wildenberg et al., 2006, Macpherson et al., 2007).  However, we observe 
that p120 ablation increases in vitro invasion of mammary carcinoma cells (Fig.25F).  
The PyMT-derived p120 KO cells are mesenchymal in morphology and behavior while 
demonstrating decreased E-cadherin, which are markers of EMT (Fig.25).  However, this 
EMT appears to be incomplete since several other EMT markers (e.g., SMA, vimentin, 
and mesenchymal cadherins) are not altered in the KO cells (data not shown).  Despite 
the lack of complete EMT, p120 ablation is sufficient for, and in fact promotes, early 
steps of the metastatic cascade (e.g., invasion) in this experimental setting. 
 p120 loss is clearly incompatible with colonization, the rate-limiting step of 
metastasis  (Fig.25&26)(Luzzi et al., 1998, Aguirre-Ghiso, 2007).  While the fate of these 
cells once in the lung has yet to be identified,  recent work challenging the understanding 
of dormancy and cell survival at secondary sites may provide an answer (Podsypanina et 
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Figure 28. Model of p120 ablation in PyMT-driven metastasis
A schematic for changes induced by p120 ablation.  All cell types are labeled 
in the key.  An increase in fibroblasts and M2 macrophages facilitates 
increased metastases of p120 positive cancer cells in the PyMT p120 KO 
mice.  In the absence of p120, CCL5 secretion is increased leading to more 
macrophages and phenotype switching to a M2 state.  Subsequently, MMP9 
production by macrophages is increased leading to increased invasion of 
cancer cells.  However, p120 negative cancer cells are colonization-
defective.  Overall, while p120 ablation promotes metastases, it is itself 
required for the final steps in the metastatic cascade.  
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 al., 2008).  Surprisingly, normal mammary epithelial cells, if injected intravenously, are 
able to reside and survive in the lungs for weeks (Podsypanina et al., 2008).  
Consistently, there is evidence that integrin-mediated proliferation signals are necessary 
for escape from dormancy by tumor cells in secondary sites (Barkan et al., 2008, Barkan 
et al., 2010). Thus, given the well-established crosstalk between integrins and cadherins, 
one possible fate of p120 null cells is dormancy.  However, it is also possible that in the 
absence of adhesion mediated survival signals (Boussadia et al., 2002, Silver et al., 
2009), p120 null cells are more susceptible to death once in the lung. A more complex 
analysis of individual p120 null cells will be necessary to understand their ultimate fate in 
the lungs.  Whether the p120 null PyMT cells are actively dying/being cleared or are 
simply dormant in the lungs has yet to be directly tested.   
 Our data highlight an emerging concept that cancer cell plasticity, rather than 
simply the irreversible acquisition of a particular state (e.g., mesenchymal), may be 
essential for metastasis. Indeed, many metastases exhibit the same degree of epithelial 
characteristics as the primary tumor (Jeschke et al., 2007, Park et al., 2007) suggesting 
that either only epithelial-like cells contribute to the metastases, or MET is taking place.  
While the former may exist in some contexts (e.g., inflammatory breast cancer and 
collective invasion), there is a wealth of direct and indirect evidence for the latter in 
mouse models and humans, respectively (Ahmed et al., 2002, Wyckoff et al., 2004, 
Jeschke et al., 2007, Park et al., 2007, Wyckoff et al., 2007, Korpal et al., 2011).  Cellular 
plasticity provides the cancer the ability to overcome different obstacles faced during the 
metastatic cascade.  
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 Given its cadherin stabilizing function (Thoreson et al., 2000, Ireton et al., 2002, 
Davis et al., 2003), p120 is uniquely suited to be a key mediator of cellular plasticity.  In 
one cadherin-centric scenario, the lack of mesenchymal cadherin stability (e.g. N-
cadherin and cadherin-11), and thus incomplete EMT, prevents lodging/outgrowth at the 
secondary site.  In another scenario, a requirement for re-epithelialization (including E-
cadherin stability) makes p120 null cells unable to colonize.  E-cadherin depletion in our 
PyMT-derived cells blocks colonization in tail vein assays (data not shown) thus 
phenocopying p120 ablation and supporting this second scenario.  Recent evidence using 
an isogenic panel of mammary carcinoma lines suggests that only the cells able to re-
express E-cadherin (i.e. undergo MET) are colonization-competent (Lou et al., 2008, 
Dykxhoorn et al., 2009).  However, simply overexpressing E-cadherin may be 
insufficient for MET in the context of p120 loss, as multiple pathways are known to 
contribute to the epithelial plasticity necessary for colonization (Korpal et al., 2011).  
Overall, our data suggest that p120 is required for late stages in the metastatic cascade 
and the inability of null cells to undergo MET prevents their outgrowth at the secondary 
site.       
 In this study, we have directly tested the relevance of the observed regions of 
p120 ablation in 10% of ductal carcinomas.  Our findings suggest that these regions are 
detrimental to overall patient health due to the microenvironmental changes that 
accompany them.  Here we have provided the beginnings of likely mechanism for these 
alterations (i.e. NFkB and ccl5).  However, downregulation and loss may not have the 
same consequences on breast cancer progression and patient outcome.  Perhaps the more 
clinically relevant discussion is what leads to the downregulation of p120 in over 50% of 
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ductal carcinoma case and more generally, how cellular p120 levels are regulated.  A 
scattering of reports has started to reveal the mechanisms of p120 level control (see p120 
levels section of Chapter 1), however much remains to be elucidated.  Future studies will 
need to focus on understanding regulation of p120 levels and its contribution to breast 
cancer metastasis.   Moreover, these studies will also need to address the cues, both 
cellular and environmental, that result in the variability of p120’s role in pathological 
processes. 
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CHAPTER V 
 
FUTURE DIRECTIONS 
 
Introduction 
 The objective of this work was to test if p120 matters in mammary development 
and breast cancer.  First, I have shown that p120 is essential for mammary development 
and terminal end bud function.  Second, I have demonstrated that p120 is required for 
PyMT-driven metastasis.  These findings have provided foundational observations for the 
Reynolds laboratory in mammary development and breast cancer research.  As such, this 
research has established the importance of p120 in these areas of research and provided 
impetus for continued work.  Indeed, these initial insights have generated a number of 
ideas yet to be explored. 
 
Mammary methods for identification of p120 binding partner functions 
 Branching of mammary glands requires coordination of a variety of processes 
including, proliferation, apoptosis, and cell motility.  These events are closely modeled in 
vitro with PMEC 3D matrigel cultures and perfectly recapitulated in vivo with gland 
reconstitution assays.  Moreover, coupled with lentivirus systems, PMECs are easily 
manipulated to repress or express whatever the target of interest.  Overall, this system 
provides a robust tool to study normal cellular function and dynamic 3D processes.  
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 A particularly interesting application of these techniques is discovery of functions 
for novel p120 binding partners.  To identify novel functions of p120, the Reynolds 
laboratory has performed a number p120 binding partner screens.  One set was performed 
utilizing cutting edge yeast two-hybrid techniques in collaboration with Hybrigenics and 
the other using a new technique developed by Dr. Andrew Smith in the Reynolds 
laboratory, RE-CLIP.  After putative binding partners have been confirmed by traditional 
techniques, one of the main challenges of such data sets is where to begin to look for 
function.  I propose that in vitro branching assays provide a good first screen of binding 
partner function in a normal (i.e., untransformed) setting. Our laboratory possesses a 
variety of lentiviral systems that, with minimal manipulation, allow for knockdown and 
addback of any protein of interest and are easily coupled with branching assays.  For 
example, our p120-depleteion experiments shown in Figure 16 are proof-of-concept 
experiments showing the power of this system. Examination of the effects of binding 
partner reduction and overexpression, as well as these effects in the absence of presence 
of p120, is fairly straightforward.  If in vitro readouts are altered, in vivo assays are then 
performed without the full costs (both financial and temporal) of traditional mouse 
genetics.  By bringing this technology to our laboratory, we are now able to explore and 
identify the functions of these novel p120 binding partners in relevant, easily manipulated 
in vitro/in vivo system.  
 
p120 isoforms and their importance during metastasis and epithelial plasticity 
 p120 isoform switching often occurs concomitantly with cadherin switching 
during EMT (Figure 4).  In fact, p120 alternative splicing (i.e. p120 isoform switch) is 
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one of the main targets of the ESRPs, key splicing-regulators of cellular plasticity 
(Warzecha et al., 2009). FGFR2 switching events occur in parallel with p120 isoform 
switching and a mouse line that marks the FGFR2 splicing events with fluorescence has 
been generated (Bonano et al., 2006).  Importantly, similar splicing reporter constructs 
have also been used in prostate cancer cells to monitor epithelial plasticity during 
metastasis (Oltean et al., 2006).  This raises the exciting possibility that the reporter mice 
and constructs, while directly monitoring FGFR2, could serve as a surrogate for 
monitoring spatial and temporal changes in p120 isoforms expression patterns.  
   Some aspects of p120 biology are isoform independent (e.g. cadherin binding), 
however emerging data suggests that isoform 1 and isoform 3 have different effects on 
cancer cell function.  For example, overexpression of isoform 1A or 3A in lung cancer 
cells leads to differential effects on invasion, Rho family of GTPase activation, and tumor 
growth (Liu et al., 2009).  Furthermore, expression of isoform 3A in mammary cells is 
able to repress Zeppo1-induced invasion (and switching to isoform 1) suggesting that this 
isoform is able to block one downstream effect of EMT driven by Zeppo1 (Slorach et al., 
2011).  Work in our laboratory by Dr. Michael Dohn indicates that only isoform 1, but 
not 3, rescues anchorage independent growth, normally blocked by p120 depletion (ABR 
unpublished results). Collectively, these data indicate that p120 isoforms play different 
roles in the cell and suggest changes in p120 isoforms is tightly linked with epithelial 
plasticity.  One of the logical next steps in our metastasis project is test whether 
individual isoforms are able to rescue colonization defects observed in p120 KO cells.  
Furthermore, cells expressing exogenous isoform 1 or 3 can also be examined by other 
assays to interrogate the isoform-specific functions during each step of the metastatic 
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cascade (e.g. transwell assays).  Once these experiments have identified isoform-specific 
roles, we can begin to address a variety of downstream questions, such as: What is the 
minimal structural requirement to confer isoform 1-specific functions?  Are isoform 1-
specific binding partners, recently discovered in the Reynolds laboratory, part of the 
isoform 1-driven event?  Do isoform-specific events require specific cadherins (e.g. 
isoform 1 and mesenchymal cadherin pairing)?.  Ultimately, our understanding of 
isoform-specific functions would benefit from a mouse expressing only isoform 1 or 3 
downstream of the endogenous p120 promoter.  Mammary-specific knockin mice 
expressing N-cadherin under the endogenous E-cadherin promoter have been generated 
by the Kemler group and could serve as a paradigm to achieve isoform specific 
expression (Kotb et al., 2011).  
 
Regulation of p120 levels 
 It is increasingly clear that p120 levels matter for normal cellular function and are 
usurped by disease states (see Introduction).  However, studies identifying the 
mechanisms surrounding these level changes are a rarity.  As demonstrated by Silvera 
and colleagues, the first step to identifying novel mechanisms of regulation is to find a 
scenario where p120 levels are altered (e.g. IBC) (Silvera et al., 2009).  Therefore, I 
propose using two systems to monitor p120 expression changes during both normal 
mammary branching and the different steps of the metastatic cascade.  First, to monitor 
changes in transcription, I suggest using reporter constructs with luciferase or GFP 
expression downstream of the p120 promoter.  Second, to monitor type and relative 
amount of translation of p120, I suggest employing previously described bicistronic 
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reporter constructs that express cap-dependent Renilla luciferase and firefly luciferase 
downstream of the p120 5’UTR (Silvera et al., 2009).  These two systems can be 
monitored during a variety of assays described herein.  Establishing the times or events 
(e.g. during branch budding) when changes in transcription and translation of p120 occur 
will allow for study of the mechanisms driving these changes. 
 
Clinical Relevance 
 p120 itself is a poor drug target as it is ubiquitously expressed and lacks 
enzymatic activity or cell-surface expression.  However, p120 status of the breast tumor 
is likely to prove useful for clinical decisions.  Low levels of p120 are correlated with 
poor outcome of breast cancer patients (Talvinen et al., 2010) and regions of p120 loss in 
mouse models induce a pro-metastatic microenvironment (chapter 4) suggesting that 
patients with low p120 expression should be monitored for progression more closely.  
Furthermore, understanding the pathways both up and downstream of p120 and how they 
are altered in specific types of breast cancer may also lead to identification of new drug 
targets for breast cancer.  Finally, since metastasis is the leading cause of mortality in 
patients, it is critical that we understand the processes that cause this endpoint.  p120 is at 
the heart of all of the known ways that cancer cells metastasize.  As such, by 
understanding p120, we begin to discover at least part of how metastasis occurs and, 
perhaps, we can identify new ways to specifically inhibit it. 
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APPENDIX A 
 
KAISO IN THE MMTV POLYOMA MIDDLE T  
MOUSE MODEL OF BREAST CANCER 
 
Introduction 
 Kaiso family members, ZBTB4, BCL-6, PLZF, and HIC-1, are implicated in 
initiation and progression of cancer (reviewed in van Roy and McCrea, 2005).  For 
example, transgenic mouse models that force the same translocations of Bcl-6 observed 
in humans, exhibit B cell lymphomas, thus presenting direct evidence that Bcl-6 
translocations are causative in B cell lymphomas (Pasqualucci et al., 2003, Baron et al., 
2004, Cattoretti et al., 2005). Furthermore, inhibition of Bcl-6 successfully treats a mouse 
model of chronic myeloic leukemia by eradicating leukemia initiating cells (Hurtz et al., 
2011).  Translocations involving PLZF are also associated with leukemia (Chen et al., 
1993).  Kaiso family member, HIC-1 is also proposed to act during tumor progression, as 
it is hypermethylated and underexpressed in tumor cells resulting in a state of resistance 
to DNA damage-induced p53-mediated apoptosis (Wales et al., 1995, Fujii et al., 1998, 
Chen et al., 2005).  Heterozygous knock out of HIC-1 and subsequent epigenetic 
silencing of the other allele results in carcinomas in male mice and sarcomas or 
lymphomas in female mice suggesting a tumor suppressive role for HIC-1 (Chen et al., 
2005).  Finally, Kaiso’s closest family member, ZBTB4 is decreased in human tumors 
and its high expression is correlated with cancer patient survival (Weber et al., 2008, Kim 
et al., 2011).  ZBTB4 transcriptional control of p21 expression likely contributes to its 
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effects on tumor progression but the exact mechanism is unclear (Weber et al., 2008, 
Yamada et al., 2009). 
 Kaiso itself is also postulated to be involved in tumor progression, however the 
exact role of Kaiso in cancer remains unclear. Kaiso represses targets known to facilitate 
metastasis (e.g. matrilysin) and to promote tumor formation (e.g. non-canonical Wnts) 
suggesting a tumor suppressive role for Kaiso.  However, Kaiso null mice exhibit 
reduced tumorigeneicity in the context of the APCMin mouse model of colon cancer 
suggesting a tumor-promoting role for Kaiso (Prokhortchouk et al., 2006).  Furthermore, 
a recent study shows that Kaiso represses tumor suppressor genes in a methylation-
dependent manner, thus Kaiso may be selectively acting as an oncogene only in areas of 
hypermethylation (Lopes et al., 2008).  Collectively, while these data provide hints that 
Kaiso and its family members are important for tumor progression, their exact functions 
in this process have yet to be discovered. 
 
Results 
 Kaiso, a p120-binding partner, was found to be upregulated in mouse models of 
colon cancer (ABR unpublished results, Prokhortchouk et al., 2006).  Therefore, we 
tested whether this upregulation was observed in other mouse models of cancer.  Indeed, 
immunofluorescent analysis for Kaiso in the PyMT mouse model of breast cancer 
demonstrated a striking upregulation of Kaiso in early hyperplastic lesions compared to 
normal mammary ducts (Fig.29A).  This strong nuclear staining was upheld in late 
carcinoma lesions (Fig.29B).  The polyclonal antibody utilized was shown to be specific 
to Kaiso since null tissue does not produce a detectable signal (data not shown).  Given 
Figure 29. Kaiso is upregulated in the PyMT mouse model 
(A) Immunofluorescence for Kaiso demonstrates an increase in PyMT-
induced lesions.  Yellow=hyperplasia White=normal duct 
(B) Immunofluorescence staing for p120 and Kaiso in PyMT p120 KO tissue. 
p120 ablation does not alter localization or intensity of Kaiso staining 
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 that Kaiso is a p120 binding partner, we analyzed PyMT p120 knockout tissue to test if 
p120 ablation affected the pronounced nuclear Kaiso signal see in wildtype lesions.  
However, loss of p120 does not affect Kaiso localization or strength of 
immunofluorescent signal (Fig. 29B).   
 To directly test the effect of Kaiso loss on PyMT tumor progression, we utilized a 
PyMT-derived cell line, 17L3C (a kind gift from Dr. Barbara Fingleton), in vitro and in 
vivo.  First, we confirmed that the strong nuclear Kaiso observed in the mouse model was 
recapitulated in 17L3C (Fig.30A).  Then, Kaiso depletion was achieved in vitro using 
three different shRNA constructs targeted to mouse Kaiso (Fig.30B).  Growth capacity of 
these cells was assessed in vitro and in vivo.  Loss of Kaiso did not alter cell growth on 
tissue culture plastic and tumor growth in the mammary fat pad was reduced in one of 
three lines (Fig.30C).  At first glance, these findings suggested that Kaiso loss did not 
consistently reduce growth.  However, analysis of tumor lysates demonstrated re-
expression of Kaiso in vivo, thus making it difficult to come to strong conclusions. 
 Given this selection for re-expression of Kaiso, we needed to switch to a system 
unable to revert back to wildtype.  Therefore, to achieve this, we crossed Kaiso null mice 
with PyMT mice (Guy et al., 1992, Prokhortchouk et al., 2006).  These crosses gave rise 
to PyMT;Kaiso+/+ (Control), PyMT;Kaiso+/- (Kaiso Het), and PyMT;Kaiso-/- (Kaiso null) 
mice.  Bi-weekly palpation of these cohorts revealed a trend toward increased time to 
tumor onset with decreased Kaiso suggesting an inverse relationship between Kaiso and 
days until detectable tumor formation (Fig.31A).  However, these data were not 
statistically significant.  Furthermore, final tumor volume at 54 days post palpation was 
unchanged in either Kasio heterozygous or null mice (Fig.31B).  Consistently, there was 
Figure 30. Kaiso depletion is selected against in vivo
(A) Immunostaining for Kaiso in PyMT-derived 17L3C cells using two different 
antibodies.  (B) Immunoblotting for Kaiso.  Depletion of Kaiso was achieved 
using three different shRNA constructs. (C) Cell growth in vitro.  Cell number 
was assessed in triplicate.  No differences in overall growth were observed.  
(D) Cell growth in vivo.  Cells were transplanted into mammary fat pads and 
calipered at the time points indicated. Mann-Whitney test *p>0.05.  
(E) Immunoblotting for Kaiso from tumor protein isolates.  Note the 
re-expression of Kaiso in tumors in vivo. 
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Figure 31.  Kaiso is not required for PyMT-driven tumorigenesis
(A) Wildtype, Kaiso  heterozygous, and Kaiso null PyMT mice were moni-
tored for tumors by palpation.  No significant difference was observed using 
a logrank test. (B) The volume of all ten mammary tumors per mouse were 
approximated by calipering (0.52*(w^2)*l=approx. volume) 54 days post 
palpation. (C) Total tumor weight was assessed.  No significant difference 
was observed by either calculation of tumor size. 
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 no statistically significant change in final tumor weight at this time point (Fig.31C).  
Thus, indicating that global Kaiso loss is insufficient to disrupt PyMT-driven tumor 
formation. 
 
Discussion 
 Despite the significant upregulation of Kaiso in even the earliest PyMT lesions, 
global Kaiso ablation did not affect tumor formation.  We postulate that this negative 
result is explained by the following possibilities.  One such possibility is that the mixed 
genetic background on which these studies were performed (i.e. part FVB, part C57/bl6) 
generated enough variability to conceal statistically significant results.  Indeed, the 
latency and metastatic outcome of the PyMT model is highly dependent on genetic 
background (Lifsted et al., 1998, Le Voyer et al., 2000, Davie et al., 2007).  However, if 
the observed upregulation of Kaiso is truly necessary for tumorigenesis, background 
differences would likely not mask the complete blockade of tumor formation in the 
absence of Kaiso.  A more likely scenario involves compensatory mechanisms by Kaiso 
family members. Similar to Kaiso, ZBTB4 binds methylated DNA and acts as a 
transcriptional repressor (Weber et al., 2008, Yamada et al., 2009). However, rather than 
the upregulation of Kaiso, ZBTB4 downregulation occurs in breast cancer (Weber et al., 
2008, Kim et al., 2011).  This downregulation appears to directly contribute to breast 
cancer progression as overexpression of ZBTB4 blocks proliferation and invasion of 
breast cancer cell lines (Kim et al., 2011).  Whether there is crosstalk between these 
events (e.g. upregulation of Kaiso and downregulation of ZBTB4) and whether disruption 
of Kaiso leads to changes in ZBTB4 signaling has yet to be addressed. 
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 While Kaiso appears to be upregulated in all PyMT cells, the physiologically 
importance of this upregulation may only occur in a specific population (e.g. cancer stem 
cells).  PyMT-derived cancer stem cell maintenance and outgrowth in the lung require 
fibroblasts in the pre-metastatic to initiate a set of signaling events, including Wnt 
signaling (Malanchi et al., 2012).  Without this stroma-initiated Wnt signaling in cancer 
stem cells, colonization is blocked.  In a GI cancer model driven by the Wnt pathway, 
Kaiso ablation slows its progression suggesting that Kaiso facilitates Wnt signaling in 
some contexts (Prokhortchouk et al., 2006).  Indeed, ongoing work in the Reynolds lab is 
focused on Wnt-Kaiso connections in this model system.  Whether these events in GI 
cancer crossover into breast cancer has yet to be tested.  The next area of work on Kaiso 
in breast cancer should focus on the cancer stem cell and Wnt signaling-driven 
colonization. 
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APPENDIX B 
 
CHARACTERIZATION OF P120-DEPLETED MCF10A CELLS 
 
Introduction 
 MCF10A cells are widely used to model untransformed mammary epithelial cell 
behavior (Debnath et al., 2002, Overholtzer et al., 2007, Mailleux et al., 2008, Simpson et 
al., 2008, Zhan et al., 2008).  We utilized this model to study the mechanism(s) 
underlying the phenotypes observed in the p120 KO mammary mice (Chapter 3).  In fact, 
use of this cell line was instrumental in identifying one of the main defects in the absence 
of p120, disrupted collective migration (Fig.12C).  Herein, we characterized our 
previously described MCF10A p120-depleted cells (Fig.12A) in a other assays not 
described in Chapter 3, namely proliferation, contractility, and stemness. 
 
Results 
 As part of the initial characterization of p120-depleted MCF10A cells, growth 
curves were generated.  No difference in growth rates were observed between control 
MCF10A cells and p120-depleted cells (Fig.32).  Interestingly, p120-depleted MCF10A 
cells exhibited serum-independent growth (Fig.32).  While parental MCF10A cells are 
growth halted in the absence of serum, p120 knockdown cells continue to proliferate.  
While interesting, the relevance of this finding is discussed below.  
  In p120 KO mammary glands, subtle but present alterations to the ductal basal 
layer (Fig.8C) and striking dissociations of the TEB cap cell layer (Fig.11C) were 
Figure 32. p120-depletion in MCF10A cells promotes 
serum-independent growth
Parental and p120-depleted MCF10A cells were grown in the presence (A) or 
absence (B) of serum and growth factors.  Cell counts were taken every day 
for four days.
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 observed.  Since this layer is thought to contain mammary progenitor cells, we wanted to 
test if p120 loss altered this population.  Previous flow cytometry analysis demonstrated 
that CD44+CD24- cells correspond to cells expressing mesenchymal or basal markers 
(i.e. myoepithelial cells)(Sheridan et al., 2006) and this population exhibits stem cell 
properties (Mani et al., 2008).  In contrast, the CD44-CD24+ cells were more 
differentiated and exhibited features of luminal cells (Mani et al., 2008).  As such, we 
used the CD44+CD24- surface marker analysis as a cursory surrogate for stemness.  To 
directly test the effects of p120-depletion on this population, we performed this flow 
cytometry analysis of MCF10A cells with and without p120.  MDA-MB-231 cells were 
used as a positive control, as these cells are reported to have a high percent of this 
population (Sheridan et al., 2006).  Indeed, 231 cells demonstrated 98.2% of cells as 
CD44+CD24- phenotype (Fig.33).  Furthermore, MCF7 cells, a negative control, 
exhibited a similar pattern to that previously published (i.e., mostly CD44-CD24+)(data 
not shown), indicating that not every cell line assessed non-discriminately mimicked 
MDA-MB-231 cells.  In our hands, MCF10A cells had a large basal population of 
CD44+CD24- cells (~70%) (Fig.33).  This is in contrast to amounts reported previously 
(17±4%)(Sheridan et al., 2006).  p120-depleted MCF10A cells had a similar amount of 
CD44+CD24- cells as control MCF10A cells suggesting that p120 depletion alone is 
insufficient to disrupt this population of basal/stem cells. 
 Since p120 is known to inhibit Rho activity (Anastasiadis et al., 2000, Perez-
Moreno et al., 2006, Wildenberg et al., 2006), we next tested the effects of p120 
reduction on readouts of Rho activity, stress fiber formation and contractility.  p120 
depletion induced a switch from cortical actin to stress fibers, a phenotype that could be 
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Figure 33. p120-depletion in MCF10A cells induces contractility
(A-B) Actin staining.  (A) MCF10A cells, p120-depleted cells, and those with 
isoform 1A or 3A added, back were stained for actin.  (B) Cells were then 
subjected to overnight serum starvation and treatment with 20 ng/mL EGF.  
Images depict the actin cytoskeleton (green) and nuclei stained with Hoecscht 
dye (blue). All scale bars = 50 μM. (C-D) Contractility assays. (C) Representa-
tive images of gels 2 days after floating are shown.  (D) A representative graph 
for the assay performed in triplicate is depicted. Student’s t-test *p<0.05
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 rescued with either p120 isoform 1A or 3A expression (Fig. 34A). Even after treatment 
with EGF, a factor that drives cortical actin formation in MCF10A cells, p120-depleted 
cells retain actin stress fibers, again indicating high Rho activity (Fig.34B). As a second 
method of monitoring of Rho activation, MCF10A cells were subjected to contractility 
assays wherein cells are embedded in floating collagen cells and the amount of 
contraction is monitored over time (Wozniak and Keely, 2005).  In this assay, p120-
depleted cells were approximately 3 times as contractile as parental MCF10A cells 
(Fig.34C,D).  Collectively, these data suggest that p120 acts to inhibit Rho in MCF10A 
cells.   
 
Discussion 
 Self-sufficiency in growth signals (e.g. serum/growth factor independent-growth), 
observed in p120-depleted MCF10A cells, is one of the hallmarks of cancer  (Hanahan 
and Weinberg, 2000).  Thus, the phenotype shown in figure 33 may prime p120-depleted 
cells for tumor formation.  Indeed, in fibroblasts, p120 facilitates contact inhibition and in 
its absence foci form (Wildenberg et al., 2006).  This growth may result from unimpeded 
receptor tyrosine kinase (RTK) signaling since in some settings E-cadherin acts an 
inhibitor of RTKs (Qian et al., 2004).  However, p120 is required for tumor growth in a 
variety of settings (Soto et al., 2008, Dohn et al., 2009) and E-cadherin is also able to 
active RTK signaling in some contexts (Pece and Gutkind, 2000).  In point of fact, 
tumors do not form in p120 mammary-specific knockout mice, and instead, p120 null 
cells are rapidly lost via anoikis (Fig.6&7).  Thus, while MCF10As and other 
immortalized cell lines exhibit growth factor independent growth in the absence of p120, 
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Figure 34. p120-depletion does not alter 
differentiation status of MCF10A cells
Parental and p120-depleted MCF10A cells and MDA-MB-231 cells were 
analyzed by flow cytometry for surface expression of CD44 and CD24 (right 
panels).  Isotype controls were utilized to set gating (left panels).
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 primary cells in vivo are likely to behave differently.  The very cues that allow for 
immortalization of tissue culture cells, as well as the signals derived from plating cells on 
rigid plastic, may cloud or alter some of the endogenous signaling in primary cells.  For 
example, Dohn et al. discuss this concept in regards to tension-dependent death, a process 
whereby cells sense high tension and induce death (Dohn et al., 2009).  p120-depleted 
MDCK cells transformed by dominant active Src are susceptible to death in the context 
of reduced external tension (e.g. in soft agar), but not while on plastic (i.e. under 
conditions of high external tension) suggesting that signals that are normally properly 
processed are not correctly interpreted when cells are on tissue culture plastic.  Thus, 3D 
in vitro or in vivo follow up experiments are necessary to interpret the relevance of the 
observed serum independent growth.  
 Similarly, while cursory studies of stemness in the context of p120-depletion in 
MCF10A cells revealed no changes, our in vivo data intimate that the progenitor 
population is reduced and/or disrupted by p120 ablation (Fig.8&11).  The Netrin and 
neogenin adhesion cues that function between body and cap cells are necessary for 
maintenance of the progenitor cells (Srinivasan et al., 2003).  Interestingly, both the 
netrin and neogenin null mammary glands phenocopy our p120 knockout TEBs.  Thus, 
while MCF10A cells provide a great starting point and indeed, some of its phenotypes are 
mimicked in vivo (e.g. disruption of collective migration), ultimately, it does not do a 
sufficient job recapitulating our in vivo findings.  As such, any conclusions reached using 
MCF10A cells would need to be repeated with PMECs in a 3D or in vivo assay. 
 In contrast to growth alterations and stemness assays, the increased Rho activity 
observed in p120-depleted MCF10A cells is likely directly relevant to p120-ablation 
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induced phenotypes observed in vivo.  Indeed, high levels of Rho activity driven by 
ablation of p190A RhoGAP phenocopies the TEB destruction observed with p120 
ablation (Heckman-Stoddard et al., 2011).  Thus, the observed increase in stress fiber 
formation and contractility, both indicative of heightened Rho activity, may be 
physiologically relevant and contribute to p120-ablation induced phenotypes. High Rho 
activity is known to disrupt adherens junctions suggesting that loss of p120 may promote 
the striking disruption of adhesion observed in the TEB by more than just decreased 
cadherin stability (Wildenberg et al., 2006, Hidalgo-Carcedo et al., 2011).  Thus, while 
we still believe that loss of junctional cadherin is the dominant phenotype, augmentation 
of Rho signaling by p120 loss may also contribute to the disruption of the TEB. 
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